Document:

EX-10.12

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.12 
 EXCLUSIVE (EQUITY) AGREEMENT 

This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher
education having powers under the laws of the State of California, and Forty Seven, Inc. (“Forty Seven”), a corporation having a principal place of business at 353 Lowell Avenue, Palo Alto, California 94301, is effective on the 19th day of
November, 2015 (“Effective Date”). 
  

	1.	BACKGROUND 

 Stanford has an assignment of one or more inventions that are useful in for the treatment
and diagnosis of cancer and other diseases and immunological disorders. Certain invention(s) were made in the course of research supported by grants from the California Institute for Regenerative Medicine (“CIRM”), The National Institutes
of Health (“NIH”), the Leukemia and Lymphoma Society (“LLS”), and The New York Stem Cell Foundation (“NYSCF”), and under a gift from the Trustees of the Virginia and D.K. Ludwig Fund for Cancer Research
(“Ludwig”). In addition, certain inventions were, in part, invented in the lab of Dr. Christopher Garcia, a Howard Hughes Medical Institute (“HHMI”) investigator and therefore were supported by HHMI. Stanford previously
licensed nonexclusively, inventions defined below as Limited Exclusive Patents to a third party. In addition, [*] was previously licensed nonexclusively [*] to another third party. Stanford wants to have the inventions perfected and marketed as soon
as possible so that resulting products may be available for public use and benefit. 
  

	2.	DEFINITIONS 

  

	2.1	“Affiliates” means any person, corporation, or other business entity which controls, is controlled by, or is under common control with Forty Seven; and for this purpose, “control” of a corporation
means the direct or indirect ownership of 50% or more of its voting stock, and “control” of any other business entity means the direct or indirect ownership of 50% or more interest in the income of such entity. 

 

	2.2	“[*] Product” means Licensed Product that [*]. 

  

	2.3	“[*] Product” means a Licensed Product that [*]. 

  

	2.4	“[*] Product” means a Licensed Product that [*]. 

  

	2.5	“Change of Control” means the following, as applied only to the entirety of that part of Forty Seven’s business that exercises all of the rights granted under this Agreement: 

 

	 	(A)	acquisition of ownership—directly or indirectly, beneficially or of record—by any non-Affiliate third person or group (within the meaning of the Exchange Act and the
rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of Forty Seven representing 50% or more of either the aggregate ordinary voting power or the aggregate equity value represented by the issued and outstanding
capital stock of Forty Seven; and/or 

  

	 	(B)	sale of all or substantially all Forty Seven’s assets and/or business in one transaction or in a series of related transactions to a non-Affiliate third
party;provided, however, that in no event shall the sale of equity or other securities for the primary purpose of financing Forty Seven be a Change of Control. 

	2.6	“Covered Product” means any product or part of a product, the manufacture, use, sale or importation of which would, but for the license granted by Stanford in the license agreement, infringe, induce
infringement or contribute to infringement of a Valid Claim. 

  

	2.7	“[*] Product” means a Licensed Product that [*]. 

  

	2.8	“Exclusive” means that, subject to Section 3.3 and Article 5, Stanford will not grant further licenses or covenants not to sue under the Licensed Patents, and Licensed Information, in the Licensed Field
of Use in the Licensed Territory. 

  

	2.9	“Exclusive Field of Use” means all fields of use. 

  

	2.10	“Exclusive Patents” means the patents and patent applications listed in Appendix D, any foreign patent application corresponding thereto, and any divisional, continuation, or reexamination application,
extension, and each patent that claims priority to, or issues or reissues from any of these patent applications, and any extensions or renewals of any such patents. 

 

	2.11	“EMA” shall mean the European Medicines Agency. 

  

	2.12	“FDA” shall mean the United States Food and Drug Administration. 

  

	2.13	“Forty Seven Patent Matters” means preparing, filing, and prosecuting broad and extensive patent claims (including any interference or reexamination actions) in Stanford’s name in the Licensed Territory
and maintaining all Exclusive Patents and the Limited Exclusive Patents. 

  

	2.14	“Fully Diluted Basis” means the total number of shares of Forty Seven’s issued and outstanding common stock, assuming: 

 

	 	(A)	the conversion of all issued and outstanding securities convertible into common stock; 

  

	 	(B)	the exercise of all issued and outstanding warrants or options, regardless of whether then exercisable; and 

  

	 	(C)	the issuance, grant, and exercise of all securities reserved for issuance pursuant to any Forty Seven stock or stock option plan then in effect. 

 

	2.15	“HHMI Indemnitees” means HHMI and its trustees, officers, employees, and agents. 

  

	2.16	“Hu5F9” means the antibody defined by the antibody sequence set forth in the Appendix H. 

  

	2.17	“Hu5F9 Licensed Product” means a Licensed Product that is the anti-CD47 antibody designated Hu5F9 and described in the Licensed Information submitted to the FDA. 

 

	2.18	“Information Product” means any product which (i) is not a Covered Product, but which incorporated into the BLA with FDA, or equivalent filing, directly or by reference, any Licensed Information, and
(ii) is a product for which Forty Seven has data and/or market exclusivity based on such Licensed Information, and against which a biosimilar or biogeneric would have to certify. 

 

	2.19	“Licensed Field of Use” means (i) with respect to the Exclusive Licensed Patents, the Exclusive Field of Use, (ii) with respect to the SIRPα Component Patents, the field of use outside the
SIRPα Component Field of Use, and (iii) with respect to the Limited Exclusive Patents, the Licensed Technology and the Licensed Information, all fields of use. 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	2.20	“Licensed Information” means technical and clinical information and data, including human trial results, associated with a Licensed Patent as set forth in Appendix E. Licensed Information does not include any
information or data [*]. 

  

	2.21	“Licensed Patent(s)” means Exclusive Patents, SIRPα Component Patents, and Limited Exclusive Patents. Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be
invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes [*], provided that [*] without mutual agreement of the Parties. 

 

	2.22	“Licensed Product” means Covered Product and Information Product. 

  

	2.23	“Licensed Technology” means the materials associated with a Licensed Patent that are available and that the inventors are willing to supply, as set forth in Appendix F, which may or may not be confidential and
is not subject to paragraph 19.1 of this Agreement. Licensed Technology does not include [*]. 

  

	2.24	“Licensed Territory” means worldwide. 

  

	2.25	“Limited Exclusive Patents” means Stanford’s U.S. Patent Application Serial Nos. [*], the U.S. patent application to be filed with respect to provisional patent [*], and U.S. Patent Application Serial
Nos. [*]; any foreign patent application corresponding thereto, and any divisional, continuation, or reexamination application, extension, and each patent that claims priority to, or issues or reissues from any of these patent applications, and any
extensions or renewals of any such patents. 

  

	2.26	“Net Sales” means all gross revenue received by Forty Seven, its Affiliates, or sublicensees, from the sale, transfer or other disposition of Licensed Product to an end user. Net Sales excludes the following
items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are separately accounted for): 

 

	 	(A)	import, export, excise, value-added, and sales taxes, and custom duties; 

  

	 	(B)	costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises or point of installation; 

 

	 	(C)	costs of installation at the place of use; and 

  

	 	(D)	credit for returns, allowances, trades, discounts, rebates and chargebacks. 

  

	2.27	“Nonroyalty Sublicensing Consideration” means any consideration attributable to a Sublicense under the Licensed Patents received by Forty Seven from a sublicensee hereunder, but excluding any consideration
for: 

  

	 	(A)	Sublicensees’ product sales (royalties on product sales by sublicensees will be treated as if Forty Seven made the sale of such product; for clarity, no double payments will be made on such product sales);

  

	 	(B)	investments in Forty Seven stock; 

  

	 	(C)	research and development expenses calculated on a fully burdened basis; 

  

	 	(D)	debt; 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	(E)	reimbursement of out-of-pocket patent prosecution and maintenance expenses for Forty Seven Patent Matters; an 

 

	 	(F)	the sale of substantially all of the business or assets of Forty Seven (or its assignee), whether by merger, sale of stock or assets, or otherwise. 

 

	2.28	“Other Licensed Product” means a Licensed Product that is not [*] Licensed Product; for clarity, such Licensed Product may include [*] product other than [*]. 

 

	2.29	“Regulatory Approval” means approval by the FDA, EMA, or equivalent agency or government body of another country permitting commercial sale of a Licensed Product in a particular country. 

 

	2.30	“SIRPα Component Field of Use” means the following: 

  

	 	(A)	A SIRPα Component for use (a) [*] or (b) [*]. 

  

	 	(B)	The SIRPα Component [*], provided that [*]. 

  

	 	(C)	The SIRPα Component [*]. 

  

	 	(D)	[*] containing SIRPα or [*] to be used solely for the purposes of [*]. 

  

	 	(E)	[*] means [*]. 

 “SIRPα Component” means [*] 

 

	2.31	“SIRPα Component Patents” means Stanford’s U.S. Patent Application, Serial Number [*], any foreign patent application corresponding thereto, and any divisional, continuation, or reexamination
application, extension, and each patent that claims priority to, or issues or reissues from any of these patent applications, and any extensions or renewals of any such patents. 

 

	2.32	“[*] Product” means a Licensed Product that [*]. 

  

	2.33	“Stanford Indemnitees” means Stanford and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, agents, faculty, representatives, and volunteers. 

 

	2.34	“Sublicense” means any agreement between Forty Seven and a third party other than Forty Seven’s Affiliates that contains a grant of rights to Stanford’s Licensed Patents, regardless of the name given
to the agreement by the parties; however, an agreement to make, have made, use or sell Licensed Products on behalf of Forty Seven or its affiliate is not considered a Sublicense. 

 

	2.35	“Valid Claim” means (a) any claim of an issued and unexpired Licensed Patent which has not been held unenforceable or invalid by a court or other governmental agency of competent jurisdiction from which
no appeal can be taken and which has not been disclaimed or admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise, or (b) a pending claim in a pending Licensed Patent application, provided that if
such pending claim does not issue as a valid and enforceable claim within [*] years from its earliest priority date, such pending claim will cease to be a Valid Claim unless and until actually issued. 

 

	2.36	Additional Definitions. Each of the following terms shall have the meaning described in the corresponding Section of this Agreement indicated below: 

 

					
	 Term
	  	Section Defined	 
	 Adjustment Event
	  	 	7.4(A)(1)	 
	 Board of Directors
	  	 	7.4(A)(2)	 

			
	 [*]
	  	[*]
	 [*]
	  	[*]
	 CIRM
	  	1

 
 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 

					
	 Claims
	  	 	10.1(B)	 
	 Deficient Product
	  	 	6.4	 
	 Disputed Breach Arbitration
	  	 	17.1	 
	 Effective Date
	  	 	Preamble	 
	 First Round
	  	 	7.3	 
	 Forty Seven
	  	 	Preamble	 
	 Generic Competition
	  	 	7.10	 
	 HHMI
	  	 	1	 
	 HHMI License
	  	 	3.5	 
	 HHMI Patents
	  	 	3.5	 

					
	 Term
	  	Section Defined	 
	 LLS
	  	 	1	 
	 Ludwig
	  	 	1	 
	 NIH
	  	 	1	 
	 Notice Period
	  	 	7.5(B)(3)	 
	 NYSCF
	  	 	1	 
	 Purchase Right
	  	 	7.4(A)	 
	 Qualifying Offering
	  	 	7.4(A)(3)	 
	 Rights Agreement
	  	 	7.4(B)(1)	 
	 Share
	  	 	7.4(A)(4)	 
	 SIRPα Component Patent Matters
	  	 	14.1(D)	 
	 Stanford
	  	 	Preamble	 
	 Terminated Patent Rights
	  	 	6.4	 
	 Termination Event
	  	 	7.4(B)	 
	 Threshold Qualifying Offering
	  	 	7.4(A)(5)	 

 
 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	3.	GRANT 

  

	3.1	Grant. Subject to the terms and conditions of this Agreement, Stanford grants Forty Seven: 

  

	 	(A)	An Exclusive license under the Exclusive Patents in the Exclusive Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory; 

 

	 	(B)	An Exclusive license under the SIRPα Component Patents outside the SIRPα Component Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory.

  

	 	(C)	An Exclusive license under the Limited Exclusive Patents to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory, but for the
non-exclusive licenses Stanford has granted to: (i) one third party [*] prior to the Effective Date, and (ii) another third party [*] prior to the Effective Date. 

 

	 	(D)	An Exclusive license under the Licensed Information to make, have made, use, import, copy, perform, display, distribute, and transmit Licensed Information for submission to the FDA and equivalent foreign regulatory
agencies, and otherwise non-exclusive. 

  

	 	(E)	An non-exclusive license for Licensed Technology to make, have made, use, import, copy, perform, display, distribute, and transmit Licensed Technology in all fields of use,
subject to Stanford’s retained rights. 

 It is understood by the Parties that solely with respect to the rights conveyed
by Stanford pursuant to Section 3.1(A) under any patent applications and patents based on [*] that such rights are [*]. Stanford will [*] patent applications and patents based on [*]. In addition, without providing prior written notice to Forty
Seven, Stanford will not [*]. 
 In the event [*], Stanford shall provide prompt written notice to Forty Seven and [*]. 

 

	3.2	Exclusivity. The licenses set forth in Section 3.1 include the right to grant Sublicense(s) under Article 4, on a Licensed
Product-by-Licensed Product and country-by-country basis in the Licensed Field of Use
beginning on the Effective Date and ending on the later of: 

  

	 	(A)	the expiration of the last-to-expire Valid Claim included in the Licensed Patents; or 

 

	 	(B)	the 10 year anniversary of the date of first commercial sale of a Licensed Product by Forty Seven or a sublicensee. Forty Seven agrees to promptly inform Stanford in writing of this first commercial sale.

 Thereafter the licenses will be fully paid up and royalty free. 

 

	3.3	Retained Rights. Stanford retains the right, on behalf of itself, Stanford Hospital and Clinics, and all other non-profit research institutions, to practice the Licensed
Patents and Licensed Information, and to use Licensed Technology, for any non-profit purpose, including sponsored research and collaborations. Forty Seven agrees that, notwithstanding any other provision of
this Agreement, it has no right to enforce the Licensed Patents against any such institution. Stanford and any such other institution have the right to publish any information included in the Licensed Technology or a Licensed Patent.

 Stanford’s retained rights set forth in this Section 3.3 with respect to Licensed Information shall be subject to
Section 19.1; provided that in the event that the inventors intend to publish or disclose any Licensed Information, the inventors will send such publication or disclosure to Forty Seven, and Forty Seven will respond within [*] days of receipt
by Forty Seven from the inventors. In the 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
event that there is not agreement of what information is subject to Section 19.1, the parties agree to meet and discuss within [*] days from the date of receipt of the response from Forty
Seven, to come to a mutual agreement, in good faith with Stanford, about any publication of Licensed Information. Stanford certifies that [*]. Accordingly, the parties agree that [*]. 

 

	3.4	Specific Exclusion. Stanford does not: 

  

	 	(A)	grant to Forty Seven any other licenses, implied or otherwise, to any patents or other rights of Stanford other than those rights granted under Licensed Patents, Licensed Information, and Licensed Technology, regardless
of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent, Licensed Information or Licensed Technology; 

 

	 	(B)	commit to Forty Seven to bring suit against third parties for infringement, except as described in Article 14; and 

  

	 	(C)	agree to furnish to Forty Seven any technology or technological information other than the Licensed Information and Licensed Technology or to provide Forty Seven with any assistance (other than transferring the Licensed
Information and Licensed Technology). 

  

	3.5	HHMI Research License. Forty Seven acknowledges that it has been informed that the [*] Patents and any patent applications and patents based on [*] (“HHMI Patents”) were developed, at least in part, by
employees of HHMI and that HHMI has a paid-up, non-exclusive, irrevocable license to use the HHMI Patents for HHMI’s research purposes, but with no right to assign
or sublicense (the “HHMI License”). This Agreement is explicitly made subject to the HHMI License. 

  

	3.6	Transfers. Upon written election from Forty Seven, Stanford will, using reasonable efforts, and at Forty Seven’s option sublicense, transfer, and/or assign to Forty Seven any or all of the rights under any
agreements or contracts between Stanford and any third party related to any of the Licensed Information and/or Licensed Technology, except to the extent prohibited by such agreements existing as of the Effective Date. In addition, upon written
election from Forty Seven, Stanford shall assign and transfer to Forty Seven all of the rights in and to the IND (as defined in Appendix E). 

  

	4.	SUBLICENSING 

  

	4.1	Permitted Sublicensing. Forty Seven may grant Sublicenses through multiple tiers of sublicensing in the Licensed Field of Use only during the Exclusive term and only if Forty Seven is developing or selling
Licensed Products directly or through its Affiliates or sublicensees. Sublicenses with any exclusivity must include diligence requirements commensurate with the diligence requirements of Appendix A. Stanford agrees that Forty Seven may apportion
without discrimination between Forty Seven and Stanford patents a commercially reasonable percentage of sublicensing payments made to Stanford pursuant to Section 4.6, provided however that Forty Seven provides Stanford with the proposed
apportionment and justification prior to Forty Seven’s payment pursuant to Section 8.1. Stanford and Forty Seven agree to meet to discuss such proposed apportionment if in Stanford’s opinion the apportionment does not reasonably
reflect the value of the Licensed Patents. 

  

	4.2	 Required Sublicensing. If Forty Seven directly or through its Affiliates or sublicensees is unable or
unwilling to serve or develop a potential market or market territory for which there is a reputable company with adequate resources willing to be a sublicensee, and such sublicensee has provided Stanford and Forty Seven with a bona fide, detailed
proposal to develop a Licensed Product for a potential market or potential territory that would not interfere with any existing or future Licensed Products of Forty Seven as reasonably demonstrated by Forty Seven in a written document to Stanford,
then Forty Seven will, at Stanford’s request, negotiate in good faith a 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	
Sublicense with any such sublicensee. Stanford would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to
improved therapeutics, diagnostics and agricultural technologies for the developing world, as applicable. 

  

	4.3	Sublicense Requirements. Any Sublicense: 

  

	 	(A)	is subject to this Agreement, except that financial terms may differ; 

  

	 	(B)	will prohibit sublicensee from paying royalties to an escrow or other similar account; 

  

	 	(C)	will expressly include the provisions of 8, 9, 10 and Section 3.5 and 19.3 for the benefit of Stanford and HHMI, and provisions that allow Forty Seven to comply with its obligations to Stanford and/or HHMI under
Article 8; and 

  

	 	(D)	will include the provisions of Section 4.4 and require the transfer of all the sublicensee’s obligations to Forty Seven, including the payment of royalties specified in the Sublicense (up to the earned royalty
rates set forth in this Agreement), to Stanford or its designee, if this Agreement is terminated by Stanford. If the sublicensee is a spin-out from Forty Seven, Forty Seven must guarantee the
sublicensee’s performance with respect to the payment of Stanford’s share of Sublicense royalties. 

  

	4.4	Litigation by Sublicensee. Any Sublicense must include the following clauses: 

  

	 	(A)	In the event sublicensee brings an action seeking to invalidate any Licensed Patent: 

  

	 	(1)	sublicensee will [*] during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by the sublicensee is both valid and infringed by a Licensed Product,
sublicensee will [*]; 

  

	 	(2)	sublicensee will [*] during the period challenge; 

  

	 	(3)	any dispute regarding the validity of any Licensed Patent shall be [*], and the parties agree [*]; and 

  

	 	(4)	sublicensee shall [*]. 

  

	 	(B)	Sublicensee will provide written notice to Stanford at least [*] prior to bringing an action seeking to invalidate a Licensed Patent. Sublicensee will include with such written notice [*]. 

 

	 	(C)	Notwithstanding the foregoing, in the event a sublicensee files a counterclaim asserting invalidity of one or more Licensed Patents in response to an actual infringement suit directed to the Licensed Patents by
Stanford, such sublicensee shall not be deemed to have initiated an action to invalidate a Licensed Patent and Sections 4.4(A) and 4.4(B) above shall not apply. 

  

	4.5	Copy of Sublicenses and Sublicensee Royalty Reports. Forty Seven will submit to Stanford a copy of each Sublicense, any subsequent amendments, and all copies of sublicensees’ royalty reports, which may in
each case be reasonably redacted for information not relevant to this Agreement. Beginning with the first Sublicense, the Chief Financial Officer or equivalent will certify annually regarding the name and number of sublicensees. 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	4.6	Sharing of Sublicensing Income. Forty Seven will pay to Stanford a portion of all Nonroyalty Sublicensing Consideration for the Sublicense of Licensed Patents and Technology, as provided below: 

 

	 	(A)	[*]% of Nonroyalty Sublicensing Consideration attributable to the Licensed Patents, up to the time [*]; 

  

	 	(B)	thereafter, [*]% of Nonroyalty Sublicensing Consideration attributable to the Licensed Patents, up to the time [*]; and 

  

	 	(C)	thereafter, [*]% of Nonroyalty Sublicensing Consideration attributable to the Licensed Patents. 

  

	4.7	Royalty-Free Sublicenses. If Forty Seven pays all royalties due Stanford from a sublicensee’s Net Sales, Forty Seven may grant that sublicensee a royalty-free or
non-cash: 

  

	 	(A)	Sublicense or 

  

	 	(B)	cross-license. 

  

	5.	SPONSOR RIGHTS 

 This Agreement is subject to Title 35 Sections
200-204 of the United States Code. Among other things, these provisions provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed
Product sold or produced in the United States be “manufactured substantially in the United States,” (subject to waivers available under applicable laws). In addition, due to CIRM funding, Forty Seven understands that this Agreement is
subject to Title 17, California Code of Regulations and the provisions of section 100607 under Title 17 place requirements on Forty Seven for access to Licensed Product in California. Forty Seven will ensure all obligations of these provisions
applicable to Forty Seven are met. Stanford will be responsible for all of Stanford’s obligations to sponsors of the Licensed Patent(s), Licensed Information, and Licensed Technology, including such obligations to NIH, CIRM, LLS, NYSCF, and
Ludwig, and all of its obligations under the agreement between Stanford and [*], and, as between Forty Seven and Stanford, will ensure all such obligations are met. 
  

	6.	DILIGENCE 

  

	6.1	Milestones. Because the invention is not yet commercially viable as of the Effective Date, Forty Seven directly or through its Affiliates, sublicensees or partners will use commercially reasonable efforts to
develop, manufacture, and sell Licensed Product and will use commercially reasonable efforts to develop markets for Licensed Product. In addition, Forty Seven will meet the milestones shown in Appendix A, and notify Stanford in writing promptly
after each milestone is met. To the extent that there are delays in any of the milestones shown in Appendix A for reasons beyond the reasonable control of Forty Seven, then the timeframe for the performance of the milestones will be subject to a day-for-day extension. Without limiting the foregoing, Forty Seven shall have the right to obtain, [*], extensions to such milestone dates shown in Appendix A. The Parties
agree that, subject to Forty Seven’s right to extend the timeline for any milestone pursuant to this Section 6.1 above, failure to meet any milestone set forth in Appendix A for [*] shall not give Stanford the right to terminate or
otherwise affect the license granted to Forty Seven for [*]; and further, that the remedy for any such failure with respect to such [*], shall be as set forth in Section 6.4. 

 

	6.2	 Progress Report. By [*] of each year, Forty Seven will submit a written annual report to Stanford covering
the preceding calendar year. The report will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government, CIRM and for Stanford to 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	
ascertain progress by Forty Seven toward meeting this Agreement’s diligence requirements. Each report will describe, where relevant: Forty Seven’s progress toward commercialization of
Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or milestones, market plans
for introduction of Licensed Product, and significant corporate transactions involving Licensed Product. Forty Seven will specifically describe how each Licensed Product is related to each Licensed Patent, and/or Licensed Information.

  

	6.3	Clinical Trial Notice. Forty Seven will notify the Stanford University Office of Technology Licensing prior to commencing any clinical trials at Stanford. 

 

	6.4	Remedy for Failure. If Forty Seven (itself or through its Affiliates, sublicensees, or partners) has failed to meet the requirements of Section 6.1 with respect to [*] (“Deficient Product”), then
Stanford shall have the right to terminate the license for such Deficient Product under this Agreement and any Licensed Patent(s) solely covering such Deficient Product in accordance with and subject to Section 15.2(B) (such Licensed Patent(s)
if terminated, the “Terminated Patent Rights”). 

  

	7.	ROYALTIES 

  

	7.1	Issue Royalty. Forty Seven will pay to Stanford a noncreditable, nonrefundable license issue royalty of $100,000, payable within [*] days of the Effective Date. 

 

	7.2	Equity Interest. As further consideration, Forty Seven will grant to Stanford [*] shares of common stock in Forty Seven. When issued, those [*] shares of common stock will represent not less than [*]% of the
common stock in Forty Seven on a Fully-Diluted Basis. The per share valuation of these shares will be provided to Stanford within [*] days of the Effective Date. Forty Seven agrees to provide Stanford with the capitalization table upon which the
above calculation is made. Forty Seven will issue shares granted to Stanford pursuant to this Section 7.2 and Section 7.3 directly to and in the name of the inventors listed in Exhibit 1 and allocated as stated in Exhibit 1, which will be
provided by Stanford to Forty Seven after the contract is fully executed. Stanford acknowledges that, in partial consideration for Forty Seven issuing such shares directly to the inventors listed above in Exhibit 1, Forty Seven intends to require
such inventors to execute inventors certificates certifying that the inventors have assigned and do assign their rights in the Licensed Patents, Licensed Technology, and Licensed Information to Stanford, and disclosing any agreements that would
provide any third party rights in or to any of the foregoing. 

  

	7.3	Anti-Dilution Protection. In addition, Forty Seven will issue Stanford, without further consideration, any additional shares of stock of the class issued pursuant to the above necessary to ensure that the total
number of shares issued Stanford does not represent less than [*]% of the shares issued and outstanding on a Fully-Diluted Basis at any time through the completion of issuance of all shares to be issued in connection with the First Round of bona
fide equity investment in Forty Seven from a single or group of investors which is both (i) at least $[*] in size and (ii) at a price per share which, when applied to stock actually outstanding immediately after such round, implies a
post-financing equity valuation of Forty Seven of at least $[*] (provided that if more than $[*] is raised as of such time, the calculation of Stanford’s percentage ownership shall be determined as if only $[*] was raised). A “First
Round” is a bona fide round of equity, warrant, option or convertible equity investment which includes all the tranches prior to the completion of the financing. This right will expire upon the issuance of all shares to be issued in connection
with such First Round, but will apply to all shares to be issued in or in connection with such First Round. 

  

	7.4	Purchase Right. 

  

	 	(A)	Stanford shall have the right, but not the obligation, to purchase for cash up to its Share of the securities issued in any Qualifying Offering on the terms, and subject to the conditions, set forth in this
Section 7.4 and Section 7.5 (the “Purchase Right”). For purposes of this Section 7.4 and Section 7.5: 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	(1)	“Adjustment Event” means the final closing of the first Threshold Qualifying Offering occurring after the date of this Agreement. 

 

	 	(2)	“Board of Directors” means (i) if Forty Seven is organized as a corporation, its board of directors, and (ii) if Forty Seven is organized as a limited liability company, Forty Seven manager(s) or
member(s) or both that have the power to direct the principal management and activities of Forty Seven, whether through ownership of voting securities, by agreement, or otherwise. 

 

	 	(3)	“Qualifying Offering” means a private offering of Forty Seven’s equity securities (or securities convertible into or exercisable for Forty Seven’s equity securities) for cash (or in satisfaction of
debt issued for cash) having its final closing on or after the date of this Agreement and which includes investment by one or more venture capital, professional angel, corporate or other similar institutional investors other than Stanford. For the
avoidance of doubt, if Forty Seven is a limited liability company, then “equity securities” means limited liability company interests in Forty Seven. 

  

	 	(4)	“Share” means: 

  

	 	(i)	[*]% with respect to any Qualifying Offering having a closing on or before the date of an Adjustment Event; or 

  

	 	(ii)	with respect to any Qualifying Offering having a closing after an Adjustment Event, but before a Termination Event, the percentage necessary for Stanford to maintain its pro rata ownership interest in Forty Seven on a
Fully-Diluted Basis. 

  

	 	(5)	“Threshold Qualifying Offering” means any Qualifying Offering which either (i) is at least $[*] in size or (ii) involves the sale to outside investors of at least [*]% of the equity securities
outstanding after such round on a Fully-Diluted Basis. 

  

	 	(6)	The parties shall construe the term “Fully-Diluted Basis” mutatis mutandis in the case where Forty Seven is organized as a limited liability company. 

 

	 	(B)	The Purchase Right shall terminate upon the earliest to occur of the following (each a “Termination Event”): 

  

	 	(1)	Stanford’s execution of an investor rights agreement or similar agreement (each a “Rights Agreement”) in connection with a Threshold Qualifying Offering so long the Rights Agreement satisfies the terms of
this Section 7.4 and Section 7.5 below; 

  

	 	(2)	Stanford purchases less than its entire Share of a Qualifying Offering; 

  

	 	(3)	Stanford fails to give an election notice within the Notice Period for a Qualifying Offering which has its final closing within [*] days of the date such notice is received by Stanford and which is closed on terms that
are the same or less favorable to the investors as the terms stated in Forty Seven’s notice to Stanford; 

  

	 	(4)	The closing of a firm commitment underwritten public offering of Forty Seven’s common stock; or 

  

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	(5)	The closing of the sale of all or substantially all of Forty Seven’s assets to a company publicly traded on one of the major recognized exchanges. 

 

	 	(C)	The Purchase Right shall not apply to the issuance of securities: (i) to employees, individuals who are members of Forty Seven’s Board of Directors as of the time of issuance, and service providers to Forty
Seven pursuant to a plan approved by Forty Seven’s Board of Directors; or (ii) as additional consideration in lending or leasing transactions; or (iii) to an entity pursuant to an arrangement that Forty Seven’s Board of Directors
determines in good faith is a strategic partnership or similar arrangement of Forty Seven (i.e., an arrangement in which the entity’s purchase of securities is not primarily for the purpose of financing Forty Seven); or (iv) to owners of
another entity in connection with the acquisition of that entity by Forty Seven. 

  

	 	(D)	For the avoidance of doubt: (i) any securities Stanford may acquire or have the right to acquire under Section 7.2 or 7.3 shall not reduce the number of securities Stanford may purchase under this
Section 7.4 or under any applicable Rights Agreement; and (ii) Stanford shall not be obligated to purchase under this Section 7.4 any Forty Seven securities it has the right to acquire under Section 7.2 or 7.3 above.

  

	7.5	Rights Agreements; Information Rights; Notice; Elections. 

  

	 	(A)	Forty Seven shall ensure that each Rights Agreement executed by Stanford in connection with a Qualifying Offering will grant to Stanford the same rights as all other investors who are parties to that Rights Agreement.
In particular, Forty Seven shall ensure that each such Rights Agreement will grant to Stanford the same right to purchase additional securities in future offerings, the same information rights, and the same registration rights as are granted to
other parties thereto, including all such rights granted to any investor designated as a “Major Investor” or other similar designation, even if Stanford is not so designated. 

 

	 	(B)	Notwithstanding any terms to the contrary contained in any applicable Rights Agreement: 

  

	 	(1)	Stanford shall not have any representation on the Board of Directors or rights to attend meetings of the Board of Directors; 

  

	 	(2)	In connection with all Qualifying Offerings, Forty Seven shall give Stanford notice of the terms of the offering, including: (i) the names of the investors, the allocation of equity securities among them and the
total amounts to be invested by each of them in such offering; (ii) pre- and post- (projected) financing capitalization table; (iii) investor presentation (if available); (iv) an introduction to the
lead investor in such offering for the purpose of discussing the lead investor’s due diligence process; and (v) such other documents and information as Stanford may reasonably request for the purpose of making an investment decision or
verifying the amount of equity securities it is entitled to purchase in such offering; and 

  

	 	(3)	Stanford may elect to exercise its Purchase Right, in whole or in part, by notice given to Forty Seven within 15 Stanford business days (i.e., days other than Saturdays, Sundays, and holidays or other days on which
Stanford is officially closed) after receipt of Forty Seven’s notice (“Notice Period”). 

  

	 	(C)	If Stanford has no information rights under a Rights Agreement and to the extent that such information has been prepared by Forty Seven for other purposes, so long as Stanford holds Forty Seven securities, Forty Seven
shall furnish to Stanford, upon request and as promptly as reasonably practicable, Forty Seven’s annual consolidated 

  

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	
financial statements and annual operating plan, including an annual report of the holders of Forty Seven’s securities, and such other information as Stanford may reasonably request from time
to time for the purpose of valuing its interest in Forty Seven. 

  

	 	(D)	Notwithstanding any notice provision in this Agreement to the contrary, any notice given under this Agreement that refers or relates to any of Section 7.4 above or this Section 7.5 shall be copied concurrently
to pvfnotices@stanford.edu; provided, however, that delivery of the copy will not by itself constitute notice for any purpose under this Agreement. 

  

	7.6	License Maintenance Fee. Beginning on the first anniversary of the Effective Date and each anniversary thereafter, Forty Seven will pay Stanford a yearly license maintenance fee as set forth in this
Section 7.6 below. Yearly maintenance payments are nonrefundable, but they are creditable each year as described in Section 7.13. 

  

	 	(A)	$20,000 on the [*] anniversary of the Effective Date; 

  

	 	(B)	$[*] on the [*] anniversary of the Effective Date; and 

  

	 	(C)	$70,000 on each anniversary of the Effective Date thereafter, until the expiration of the last Valid Claim included in the Licensed Patents. 

 

	7.7	Milestone Payments. Forty Seven will pay Stanford the following milestone payments: 

  

	 	(A)	Due one time on the first Licensed Product to achieve the milestones set forth in this Section 7.7(A) below: 

  

	 	(1)	$75,000 upon initiation of Phase II clinical trial with FDA or equivalent in foreign jurisdiction, whichever one occurs first; 

  

	 	(2)	$[*] upon [*]; 

  

	 	(3)	$[*] upon [*]; 

  

	 	(4)	$[*] upon [*]; 

  

	 	(5)	$[*] upon [*]. 

  

	 	(B)	Due one time on the second Licensed Product to achieve the milestones set forth in this Section 7.7(B) below: 

  

	 	(1)	$[*] upon [*]; 

  

	 	(2)	$[*] upon [*]; 

  

	 	(3)	$[*] upon [*]; 

  

	 	(4)	$[*] upon [*]; 

  

	 	(5)	$[*] upon [*]. 

  

	 	(C)	Due one time on the third Licensed Product to achieve the milestones set forth in this Section 7.7(C) below: 

  

	 	(1)	$[*] upon [*]; 

  

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	(2)	$[*] upon [*]; 

  

	 	(3)	$[*] upon [*] 

  

	 	(4)	$[*] upon [*]; 

  

	 	(5)	$[*] upon [*]. 

 Notwithstanding anything to the contrary in this Agreement, [*], as set forth
in this Section 7.7 above, shall be payable only one time, upon [*]; provided, however, that if [*] then the milestone payment will be [*]. 

It is further understood that in the event Forty Seven receives a milestone payment from a sublicensee and the milestone event giving rise to
such payment would also trigger a payment obligation on the part of Forty Seven under this Section 7.7, Forty Seven shall [*], which shall [*], and [*]. 
  

	7.8	Earned Royalty. 

  

	 	(A)	Forty Seven will pay Stanford earned royalties on annual Net Sales of Hu5F9 Licensed Product as follows: 

  

			
	 Annual Net Sales of Licensed
Product
	  	 Royalty Rate

	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

  

	 	(B)	Forty Seven will pay Stanford earned royalties on annual Net Sales of Other Licensed Product as follows: 

  

			
	 Annual Net Sales of Licensed
Product
	  	 Royalty Rate

	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	(C)	If Forty Seven is required to pay any amounts with respect to any Licensed Product under agreements for patent rights or other technologies which Forty Seven or its affiliate, in its reasonable judgment, determines are
desirable to license or acquire (including for the method of use or manufacture thereof), Forty Seven may deduct up to [*] of the amounts actually paid on Net Sales with respect to such Licensed Product from the royalty payments due Stanford with
respect to such Licensed Product. Notwithstanding the foregoing provisions of this Section 7.8(C), in no event shall the royalties due to Stanford pursuant to Section 7.8 be so reduced to less than fifty percent (50%) of the amount that
would otherwise be due to Stanford hereunder. 

  

	7.9	Combination Product. In the event that a Licensed Product is sold in combination with another product, component or service for which no royalty would be due hereunder if sold separately, Net Sales from such
combination sales for purposes of calculating the amounts due under this Article 7 shall be calculated by multiplying the Net Sales of the combination product or service by the fraction A/(A + B), where A is the average gross selling price during
the preceding calendar quarter of the Licensed Product sold separately and B is the average gross selling price during the preceding calendar quarter of the other product(s), component(s) or service(s). In the event that separate sales of the
Licensed Product and/or of the other product(s), component(s) or service(s) were not made during the preceding calendar quarter, then the Net Sales on the combination product shall be reasonably allocated between such Licensed Product, and such
other product(s), component(s) or service(s) based upon their relative importance and proprietary protection as mutually agreed upon by Stanford and Forty Seven. 

  

	7.10	Generic Competition. In any country where Generic Competition exists, as long as such Generic Competition exists in such country, the royalty otherwise due under Section 7.8 above with respect to Net Sales
of the corresponding Licensed Product in such country shall be reduced by [*]. For purposes of this Agreement, “Generic Competition” means that a product is being sold by a third party in such country and such product [*]. Notwithstanding
the foregoing provisions of this Section 7.10, in no event shall the royalties due to Stanford pursuant to Section 7.8 be so reduced to less than [*] of the amount that would otherwise be due to Stanford hereunder. 

 

	7.11	Single Royalty. No more than one royalty payment under this Agreement shall be due to Stanford with respect to a sale of a particular Licensed Product (e.g., even if such Licensed Product is covered by multiple
Valid Claims and Licensed Information). Multiple royalties shall not be payable because any Licensed Product, or its manufacture, sale or use, is covered by more than one claim within the Licensed Patents. No royalty shall be payable under
Section 7.8 with respect to sales or other transfers of Licensed Products among Forty Seven, its Affiliates and sublicensees for resale (but the subsequent resale of such Licensed Product shall be included within the computation of Net Sales),
nor shall a royalty be payable under Section 7.8 with respect to any Licensed Products transferred (for no more than the cost of the Licensed Product) for use in research and/or development, clinical trials, compassionate use programs, as
donations to non-profit institutions or government agencies, as promotional free samples or the like. 

  

	7.12	Earned Royalty if Forty Seven Challenges the Patent. Notwithstanding the above, should Forty Seven bring an action seeking to invalidate any Licensed Patent, Forty Seven will pay royalties to Stanford [*] during
the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by Forty Seven is both valid and infringed by a Licensed Product, Forty Seven will pay royalties [*]. Notwithstanding the
foregoing, in the event Forty Seven files a counterclaim asserting invalidity of one or more Licensed Patents in response to an actual infringement suit directed to the Licensed Patents by Stanford, Forty Seven shall not be deemed to have initiated
an action to invalidate a Licensed Patent and this Section 7.12 shall not apply. For the purposes of this Section 7.12, [*]. 

  

	7.13	Creditable Payments. The license maintenance fee for a year may be offset against earned royalty payments due on Net Sales occurring in that year. 

 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 For example: 
  

	 	(A)	if Forty Seven pays Stanford a $10 maintenance payment for year Y, and according to Section 7.8 $15 in earned royalties are due Stanford for Net Sales in year Y, Forty Seven will only need to pay Stanford an
additional $5 for that year’s earned royalties. 

  

	 	(B)	if Forty Seven pays Stanford a $10 maintenance payment for year Y, and according to Section 7.8 $3 in earned royalties are due Stanford for Net Sales in year Y, Forty Seven will not need to pay Stanford any earned
royalty payment for that year. Forty Seven will not be able to offset the remaining $7 against a future year’s earned royalties. 

  

	7.14	Obligation to Pay Royalties. A royalty is due Stanford under this Agreement for each Licensed Product sold under the licenses granted. For convenience’s sake, the amount of that royalty is calculated using
Net Sales. Nonetheless, if certain Licensed Products are [*], and those Licensed Products are [*], Forty Seven will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products. 

 

	7.15	No Escrow. Forty Seven shall not pay royalties into any escrow or other similar account. 

  

	7.16	Currency. Forty Seven will calculate the royalty on sales in currencies other than U.S. Dollars using the appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of
business on the last banking day of each calendar quarter. Forty Seven will make royalty payments to Stanford in U.S. Dollars. 

  

	7.17	Non-U.S. Taxes. Forty Seven will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any
payments due to Stanford. 

  

	7.18	Interest. Any payments not made when due will bear interest at the lower of (a) the Prime Rate published in the Wall Street Journal plus [*] basis points, or (b) the maximum rate permitted by law.

  

	8.	ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

  

	8.1	Quarterly Earned Royalty Payment and Report. Beginning with the first sale of a Licensed Product by Forty Seven, its affiliate, or a sublicensee, Forty Seven will submit to Stanford a written report (even if
there are no sales) and an earned royalty payment within [*] days after the end of each calendar quarter. This report will be in the form of Appendix B and will state the number, description, and aggregate Net Sales of Licensed Product during the
completed calendar quarter. The report will include an overview of the process and documents relied upon to permit Stanford to understand how the earned royalties are calculated. With each report Forty Seven will include any earned royalty payment
due Stanford for the completed calendar quarter (as calculated under Section 7.8). 

  

	8.2	No Refund. In the event that a validity or non-infringement challenge of a Licensed Patent brought by Forty Seven is successful, Forty Seven will have no right to recoup
any royalties paid before or during the period challenge. 

  

	8.3	Termination Report. Forty Seven will pay to Stanford all applicable unpaid royalties accrued as of the date of termination and submit to Stanford a written report within [*] days after the license terminates.
Forty Seven will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold. 

 

	8.4	Accounting. Forty Seven will maintain records showing manufacture, importation, sale, and use of a Licensed Product for [*] years from the date of sale of that Licensed Product. Records will 

 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	
include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related information in sufficient detail
to enable Stanford to determine the royalties payable under this Agreement. 

  

	8.5	Audit by Stanford. Upon reasonable advance notice and during normal business hours, Forty Seven will allow Stanford or its designee to examine Forty Seven’s records kept in accordance with Section 8.4,
no more than [*], to verify payments made by Forty Seven under this Agreement. 

  

	8.6	Paying for Audit. Stanford will pay for any audit done under Section 8.5. But if the audit reveals an underreporting of earned royalties due Stanford of [*] or more for the period being audited, Forty Seven
will pay the out-of-pocket audit costs reasonably incurred by Stanford. 

  

	8.7	Self-audit. Forty Seven will conduct an independent audit of sales and royalties at least [*] if annual sales of Licensed Product are over $[*]. The audit will address, at a minimum, the amount of gross sales by
or on behalf of Forty Seven during the audit period, the amount of funds owed to Stanford under this Agreement, and whether the amount owed has been paid to Stanford and is reflected in the records of Forty Seven. Forty Seven will submit the
auditor’s report promptly to Stanford upon completion. Forty Seven will pay for the entire cost of the audit. 

  

	9.	EXCLUSIONS AND NEGATION OF WARRANTIES 

  

	9.1	Negation of Warranties. Stanford provides Forty Seven the rights granted in this Agreement AS IS and WITH ALL FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or
implied. Among other things, Stanford disclaims any express or implied warranty: 

  

	 	(A)	of merchantability, of fitness for a particular purpose; 

  

	 	(B)	of non-infringement; or 

  

	 	(C)	arising out of any course of dealing. 

  

	9.2	No Representation of Licensed Patent. Forty Seven also acknowledges that Stanford does not represent or warrant: 

  

	 	(A)	the validity or scope of any Licensed Patent; or 

  

	 	(B)	that the exploitation of Licensed Patent, Licensed Information or Licensed Technology will be successful. 

  

	10.	INDEMNITY 

  

	10.1	Indemnification. 

  

	 	(A)	Forty Seven will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind arising out of or related to the exercise of any rights granted Forty Seven under this Agreement or the breach
of this Agreement by Forty Seven. Stanford agrees to inform Forty Seven promptly in writing of any claim or threatened claim that may give rise to an obligation of indemnity under this Agreement of which Stanford becomes aware. Forty Seven’s
obligations to a Stanford Indemnitee under this section shall be relieved only to the extent that Forty Seven can demonstrate material prejudice caused by (1) Stanford’s failure to provide adequate or timely notice of the claim;
(2) the Stanford Indemnitee making an admission regarding such claim without the prior written consent of Forty Seven, which consent shall not be unreasonably withheld; and (3) the 

 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	
gross negligence or willful misconduct of the Stanford Indemnitee. Stanford will provide Forty Seven with the first right to defend and settle and exclusive control of the defense or settlement
of each such claim, provided that Forty Seven must do so in a manner that does not adversely affect Stanford’s interests and it must obtain Stanford’s prior consent to any settlement (such consent not to be unreasonably withheld or
delayed). Notwithstanding the foregoing, Forty Seven shall have no obligation for any claim that may be the subject of this Section 10.1(A) to the extent resulting from any Stanford Indemnitee’s conduct of the clinical trials of Hu5F9
until and to the extent Forty Seven and Stanford enter into an agreement for the conduct of any such clinical trial in which Forty Seven shall indemnify Stanford for claims arising from such clinical trial, which agreement, upon execution by the
parties shall govern their respective indemnification obligations with respect to such clinical trial. 

  

	 	(B)	HHMI Indemnitees will be indemnified, defended by counsel acceptable to HHMI, and held harmless by Forty Seven from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind
or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “Claims”), based upon, arising out of, or otherwise relating to this Agreement, including without limitation
any cause of action relating to product liability. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI
Indemnitee. Notwithstanding Section 10.2 or any other provision of this Agreement, Forty Seven’s obligation to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph will not be subject to any limitation or exclusion
of liability or damages or otherwise limited in any way. 

  

	10.2	No Indirect Liability. Neither party shall be liable for any special, consequential, lost profit, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this
Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise. 

  

	10.3	Workers’ Compensation. Forty Seven will comply with all statutory workers’ compensation and employers’ liability requirements for activities performed under this Agreement. 

 

	10.4	Insurance. Prior to the first testing of a Licensed Product by Forty Seven in a human and thereafter during the term of this Agreement, Forty Seven will maintain Comprehensive General Liability Insurance,
including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of Forty Seven and its sublicensees. The insurance will provide minimum limits of liability of $[*] and will include all
Stanford Indemnitees and HHMI Indemnitees as additional insureds. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within [*] days of the Effective Date of this Agreement, Forty Seven will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Forty Seven
will provide to Stanford [*] days prior written notice of cancellation or material change to this insurance coverage. Forty Seven will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for
at least the minimum limits set forth above. All insurance of Forty Seven will be primary coverage; insurance of Stanford Indemnitees and HHMI Indemnitees will be excess and noncontributory. 

 

	11.	EXPORT 

 Forty Seven and its Affiliates and sublicensees shall comply with all United States laws and
regulations controlling the export of licensed commodities and technical data. (For the purpose of this paragraph, “licensed commodities” means any article, material, or supply, but does not include information; and “technical
data” means tangible or intangible technical information that is subject to U.S. export 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals, and instructions.) These laws and regulations may include, but are
not limited to, the Export Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions
regulations administered by the U.S. Department of the Treasury (31 CFR 500-600). 
 Among other things, these laws
and regulations prohibit or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. Forty Seven hereby gives written assurance that it will comply with, and will cause
its Affiliates and sublicensees to comply with, all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or sublicensees, and that it will
indemnify, defend and hold Stanford and HHMI Indemnitees harmless for the consequences of any such violation. 
  

	12.	MARKING 

 Before any Licensed Patent issues, Forty Seven will mark Licensed Product with the words
“Patent Pending.” Otherwise, Forty Seven will mark Licensed Product with the number of any issued Licensed Patent, to the extent required by the applicable patent marking laws. 

 

	13.	STANFORD NAMES AND MARKS 

 Forty Seven will not use (i) Stanford’s or HHMI’s name or other
trademarks, (ii) the name or trademarks of any organization related to Stanford or HHMI, or (iii) the name of any Stanford or HHMI faculty member, employee, student, or volunteer, without the prior written consent of the party (Stanford or
HHMI, as the case may be) whose name or trademark is being used. Permission may be withheld at Stanford’s or HHMI’s sole discretion. This prohibition includes, but is not limited to, use in press releases, advertising, marketing materials,
other promotional materials, presentations, case studies, reports, websites, application or software interfaces, and other electronic media. Notwithstanding the foregoing, Forty Seven may, without prior permission of Stanford, reasonably utilize
Stanford’s name in statements of fact (provided such statements do not imply endorsement of Forty Seven’s products), in legal proceedings, patent filings, and regulatory filings, and/or any such individual’s name upon his or her prior
written consent. 
  

	14.	PROSECUTION AND PROTECTION OF PATENTS 

  

	14.1	Patent Prosecution. 

  

	 	(A)	Following the Effective Date, Forty Seven will be responsible for Forty Seven Patent Matters. Forty Seven will use commercially reasonable efforts with respect to the Forty Seven Patent Matters and in doing so will act
in good faith irrespective of other patents, patent applications, or other rights that Forty Seven may possess. Forty Seven will consult with Stanford on Forty Seven Patent Matters and advise Stanford of any substantive actions in prosecuting the
claims. Stanford will have final approval on any Forty Seven Patent Matters, such approval not to be unreasonably withheld, conditioned, or delayed. To aid Forty Seven in this process, Stanford will promptly provide all information, execute and
deliver all documents, and do all other acts as Forty Seven shall reasonably request from time to time. If at any time Forty Seven fails to satisfy the standards of this Section 14.1(A), Stanford may, upon [*] days’ notice, terminate this
Section 14.1(A). 

  

	 	(B)	Forty Seven will reimburse Stanford for Stanford’s reasonable out-of-pocket costs incurred in complying with such requests. Stanford
and Forty Seven agree that Stanford is the client of record for the attorney prosecuting the Licensed Patents included in the Forty Seven Patent Matters and agree to have Appendix C fully executed by the appropriate parties upon execution of this
Agreement. At Stanford’s request, Forty Seven 

  

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	 	
will provide all information and assistance to Stanford to ensure that the Licensed Patent is as extensive as possible. If Stanford has terminated Section 14.1(A), any agreement in the form
of Appendix C will be deemed to be amended immediately without prior action by any party to revise Appendix C, Section 1 to require the Firm (as defined in Appendix C) to interact directly with Stanford only. 

 

	 	(C)	In the event Forty Seven decides to abandon any Licensed Patent(s) included in the Forty Seven Patent Matters, Forty Seven shall give Stanford reasonable prior written notice. Stanford may in its discretion continue to
prosecute and maintain such Licensed Patent(s) at its expense, in which case such Licensed Patent(s) shall [*]. 

  

	 	(D)	Subject to the following terms of this Section 14.1(D) below, Stanford will be solely responsible for preparing, filing, and prosecuting and maintaining the SIRPα Component Patents (“SIRPα Component
Patent Matters”). With respect to SIRPα Component Patent Matters, and/or in the event Stanford controls the preparation, filing, prosecution and maintenance of any of the other Licensed Patents, Stanford agrees to (i) keep Forty Seven
reasonably informed as to the SIRPα Component Patent Matters, and the preparation, filing, prosecution and maintenance of such other Licensed Patents, (ii) furnish to Forty Seven copies of material documents and communications relevant to
such filing, prosecution and maintenance, and (iii) allow Forty Seven a reasonable opportunity to comment on patent strategy and material documents filed with any patent office with respect to the SIRPα Component Patent Matters and such
other Licensed Patents and incorporate Forty Seven’s reasonable comments and suggestions with respect thereto as mutually agreed. In the event Stanford elects to abandon any patent or application within the Licensed Patents, it shall notify
Forty Seven and any other licensee(s) of the Licensed Patents at least [*] days in advance of the next applicable deadline with the applicable patent office, in which case Forty Seven and any such other licensee(s) shall discuss and agree on the
control and expense of the prosecution and maintenance of such patents and applications (including any patent issuing therefrom). In the event of any disagreement as between Forty Seven and the one third party licensee to which Stanford has granted
a license under the SIRPα Component Patent in the SIRPα Component Field of Use prior to the Effective Date concerning the preparation, filing, prosecution, maintenance or other matters in respect of the SIRPα Component Patent Matters,
Stanford and Forty Seven shall meet and discuss such disagreement, and Stanford shall be responsible for final decisions concerning such disagreement with respect to the SIRPα Component Patent Matters, taking into account the rights and
interests of such licensees of the SIRPα Component Patent. 

  

	14.2	Patent Costs. Within [*] days after receiving a statement from Stanford, Forty Seven will reimburse Stanford: 

  

	 	(A)	for the following approximate amounts to offset Exclusive Patent’s and Limited Exclusive Patent’s patenting expenses, including any interference or reexamination matters, incurred by Stanford before the
Effective Date: (i) $466,262.92 to be invoiced upon the Effective Date; and $466,262.92 to be invoiced upon the [*] of the Effective Date; and 

  

	 	(B)	for the following out-of-pocket Exclusive Patent’s and Limited Exclusive Patent’s patenting expenses, including any interference
or reexamination matters, reasonably incurred by Stanford after the Effective Date, other than any such expenses incurred by Stanford for any Terminated Patent Rights: 

 

	 	(1)	[*] of Forty Seven Patent Matters with respect to the Exclusive Patents; 

  

	 	(2)	[*] of Forty Seven Patent Matters with respect to the Limited Exclusive Patents. 

 In all
instances, Stanford will pay the fees prescribed for large entities to the United States Patent and Trademark Office. 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	14.3	Infringement Procedure. Forty Seven will promptly notify Stanford if it believes a third party infringes a Licensed Patent or if a third party files a declaratory judgment action with respect to any Licensed
Patent. During the Exclusive term of this Agreement and if Forty Seven is developing Licensed Product, Forty Seven will have the right to institute a suit against or defend any declaratory judgment action initiated by this third party that relates
to a Limited Exclusive Patent and/or an Exclusive Patent as provided in Section 14.4 through and including Section 14.9. Without limiting the foregoing, in the event that any action described in this Section 14.3 relates to any claims
in the SIRPα Component Patents, the parties agree to meet and discuss any action as to the SIRPα Component Patents, and come to a mutual agreement with respect to such actions before moving forward as provided in Section 14.7.

  

	14.4	Forty Seven Suit. Forty Seven, itself or through a designee, has the first right to institute suit, or defend any action for declaratory judgment, relating to the Exclusive Patents and/or the Limited Exclusive
Patents, and may name Stanford, subject to the requirements of this Section 14.4, as a party for standing purposes. If Forty Seven decides to institute suit, it will notify Stanford in writing. Forty Seven will bear the entire cost of the
litigation. Stanford may be named as a party in a suit initiated by Forty Seven (other than in accordance with Section 14.5 below) only if: 

  

	 	(A)	Forty Seven’s and Stanford’s respective counsel recommend that such action is necessary in their reasonable opinion to achieve standing, or a court has required or will require such joinder to pursue the
action; 

  

	 	(B)	Stanford is not the first named party in the action; and 

  

	 	(C)	the pleadings and any public statements about the action state that Forty Seven is pursuing the action and that Forty Seven has the right to join Stanford as a party. 

 

	14.5	Joint Suit. If Stanford and Forty Seven so agree, they may institute suit or defend the declaratory judgment action jointly. If so, they will: 

 

	 	(A)	prosecute the suit in both their names; 

  

	 	(B)	bear the out-of-pocket costs [*]; 

  

	 	(C)	share any recovery or settlement [*]; and 

  

	 	(D)	agree how they will exercise control over the action. 

  

	14.6	Stanford Suit. If Forty Seven does not initiate an enforcement action within [*] days of a request by Stanford to do so or Forty Seven does not elect to control a declaratory judgment action within [*] days of
receiving notice that such action has been filed, in each case relating to the Exclusive Patents and/or the Limited Exclusive Patents, Stanford has the right to institute and prosecute such a suit or defend any such declaratory judgment action. If
Stanford decides to institute suit, it will notify Forty Seven in writing. If Forty Seven does not notify Stanford in writing that it desires to jointly prosecute the suit within [*] days after the date of the notice, Forty Seven will [*]. Stanford
will bear the entire cost of the litigation and will [*]. 

  

	14.7	SIRPα Component Patents Suit. In the event of an infringement or declaratory action relating to a Licensed Patent that is SIRPα Component Patent, Forty Seven and Stanford will advise the
other, and will meet to discuss next steps to take about the known or suspected infringement. Such steps will also consider the rights and interests of the one third party licensee to which Stanford has granted a license under the SIRPα
Component Patent in the SIRPα Component Field of Use prior to the Effective Date. 

  

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	14.8	Recovery. If Forty Seven sues under Section 14.4, then any recovery in excess of any unrecovered litigation costs and fees will be shared with Stanford as follows: 

 

	 	  	[*] 

  

	14.9	Abandonment of Suit. If either Stanford or Forty Seven commences a suit and then wants to abandon the suit, it will give timely notice to the other party. The other party if it so desires may continue prosecution
of the suit at its own expense, in which case after Stanford and Forty Seven shall agree on the sharing of expenses and any recovery in the suit. 

  

	15.	TERMINATION 

  

	15.1	Termination by Forty Seven. Forty Seven may terminate this Agreement in its entirety or with respect to any Licensed Patent by giving Stanford written notice at least 30 days in advance of the effective date of
termination selected by Forty Seven. 

  

	15.2	Termination by Stanford. 

  

	 	(A)	Stanford may also terminate this Agreement if Forty Seven on 30 days’ written notice: 

  

	 	(1)	is in material default in the payment of amounts due hereunder or the provision on any report; 

  

	 	(2)	is not using commercially reasonable efforts in developing and commercializing Licensed Product; 

  

	 	(3)	is in material breach of any provision; or 

  

	 	(4)	provides any materially false report. 

  

	 	(B)	In the event Forty Seven misses a milestone described in Appendix A, Stanford may terminate the license for the applicable Deficient Product under this Agreement for which such milestone was missed and any Licensed
Patent(s) solely covering such Deficient Product, subject to Forty Seven’s right to extend the timeline for milestones pursuant to Section 6.1. 

  

	 	(C)	Termination under this Section 15.2 will take effect 30 days after written notice by Stanford unless Forty Seven remedies the problem in that 30-day period.

  

	15.3	Surviving Provisions. Surviving any termination or expiration are: 

  

	 	(A)	Forty Seven’s obligation to pay royalties accrued or accruable; 

  

	 	(B)	any claim of Forty Seven or Stanford, accrued or to accrue, because of any breach or default by the other party; 

  

	 	(C)	the provisions of Articles 8, 9, 10, 13, 17, and 19; and Section 3.5 and 15.3. 

  

	 	(D)	any Sublicenses granted hereunder. 

  

	16.	CHANGE OF CONTROL AND NON-ASSIGNABILITY 

  

	16.1	Change of Control. If there is a Change of Control, Forty Seven will [*] upon assignment of this Agreement per Section 16.2. In no event shall [*]. 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	16.2	Conditions of Assignment under Change of Control. Forty Seven may assign this Agreement as part of a Change of Control upon prior and complete performance of the following conditions: 

 

	 	(A)	Forty Seven must give Stanford [*] written notice of the assignment, including the new assignee’s contact information; and 

  

	 	(B)	the new assignee must agree in writing to Stanford to be bound by this Agreement; and 

  

	 	(C)	[*], provided that [*] Change of Control under this Agreement only. 

  

	16.3	After the Assignment. Upon a permitted assignment of this Agreement pursuant to Article 16, Forty Seven will be released of liability under this Agreement and the term “Forty Seven” in this Agreement
will mean the assignee. 

  

	16.4	Bankruptcy. In the event of a bankruptcy or insolvency, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development and sales of Licensed
Product. 

  

	16.5	Nonassignability of Agreement. Except in conformity with Sections 16.2 and 16.4, this Agreement is not assignable by Forty Seven under any other circumstances and any attempt to assign this Agreement by Forty
Seven is null and void. 

  

	17.	DISPUTE RESOLUTION 

  

	17.1	Dispute Resolution by Arbitration. Subject to Section 17.5, any dispute between the parties regarding [*], or regarding [*] under this Agreement will be settled by arbitration in accordance with the JAMS
Arbitration Rules and Procedures. In addition, if Forty Seven disputes in good faith any alleged material breach or default of the Agreement within the [*] cure period specified in Section 15.2 such dispute shall settled by arbitration in
accordance with the JAMS Arbitration Rules and Procedures (“Disputed Breach Arbitration”) and this Agreement shall not terminate until the arbitrator determines that such default or material breach was committed, and Forty Seven fails to
cure such breach within [*] after such determination; provided that the Parties will use good faith efforts to complete the Disputed Breach Arbitration within [*] following the initiation of such arbitration, and will instruct the arbitrator
to establish reasonable procedures to facilitate and complete such arbitration within such [*] period. The parties are not obligated to settle any other dispute that may arise under this Agreement by arbitration. Notwithstanding the foregoing, no
dispute affecting the rights or property of HHMI shall be subject to the arbitration provisions set forth in this Article 17. 

  

	17.2	Request for Arbitration. Either party may request such arbitration. Stanford and Forty Seven will mutually agree in writing on a third party arbitrator within [*] of the arbitration request. The arbitrator’s
decision will be final and nonappealable and may be entered in any court having jurisdiction. 

  

	17.3	Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery.

  

	17.4	Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually agree in writing to another place. 

 

	17.5	Patent Validity. Any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction
in that forum. 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	18.	NOTICES 

  

	18.1	Legal Action. Forty Seven will provide written notice to Stanford at least [*] prior to bringing an action seeking to invalidate any Licensed Patent or a declaration of
non-infringement. Forty Seven will include with such written notice [*]. 

  

	18.2	All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent as follows: 

All general notices to Forty Seven are mailed or emailed to: 

Jonathan MacQuitty 
 Forty Seven
Inc. 
 [*] 
 With a copy to:

 Vern Norviel 
 Wilson
Sonsini Goodrich & Rosati 
 650 Page Mill Road 

Palo Alto, CA 94304 

vnorviel@wsgr.com 
 All financial
invoices to Forty Seven (i.e., accounting contact) are e-mailed to: 
 Jonathan MacQuitty 

[*] 
 All progress report
invoices to Forty Seven (i.e., technical contact) are e-mailed to: 
 Jonathan MacQuitty 

[*] 
 All general notices to
Stanford are e-mailed or mailed to: 
 Office of Technology Licensing 

3000 El Camino Real 
 Building 5,
Suite 300 
 Palo Alto, CA 94306-2100 

info@otlmail.stanford.edu 
 All
payments to Stanford are mailed to: 
 Stanford University 

Office of Technology Licensing 

Department #44439 
 P.O. Box 44000

 San Francisco, CA 94144-4439 

All progress reports to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 

3000 El Camino Real 
 Building 5,
Suite 300 
 Palo Alto, CA 94306-2100 

info@otlmail.stanford.edu 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Any notice related to Section 7.4 or Section 7.5 (Stanford Purchase Rights) shall be
copied concurrently to pvfnotices@stanford.edu 
 Either party may change its address with written notice to the other party. 

 

	19.	MISCELLANEOUS 

  

	19.1	Confidentiality. Stanford shall maintain the terms of this Agreement as well as the reports and any information provided by Forty Seven to Stanford hereunder, including information provided pursuant to Sections
4.5, 6.2, 8.1, 8.3, 8.5, and 8.7 of this Agreement, and the Licensed Information (including without limitation the IND, as defined in Appendix E), in confidence and not disclose such information or reports to any third party, except as required by
law and except that Stanford may share the terms of this Agreement with HHMI under terms of confidentiality. Stanford’s obligation of confidentiality hereunder shall be fulfilled by using at least the same degree of care with Forty Seven’s
confidential information as Stanford uses to protect its own confidential information. Stanford’s shall have no obligation hereunder to refrain from disclosing or using the following: 

 

	 	(a)	Information that, at the time of disclosure, is generally available to the public; 

  

	 	(b)	Information that becomes part of the public domain or publicly known or available by publication or otherwise, not due to any unauthorized act or omission on the part of Stanford; 

 

	 	(c)	Information that is disclosed to the Stanford by third parties who was not under a duty of confidentiality to Forty Seven; 

  

	 	(d)	Information that has been independently developed by Stanford without use of or reference to information provided by Forty Seven; and 

 

	 	(e)	Information that is required to be disclosed by a court of competent jurisdiction. 

  

	19.2	Waiver. No term of this Agreement can be waived except by the written consent of the party waiving compliance. 

  

	19.3	Third Party Beneficiary. HHMI is not a party to this Agreement and has no liability to any licensee, sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of
this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

  

	19.4	Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of California, United States of America, applicable to agreements negotiated, executed, and performed within
California. 

  

	19.5	Entire Agreement. The parties have read this Agreement and agree to be bound by its terms, and further agree that it constitutes the complete and entire agreement of the parties and supersedes all previous
communications, oral or written, and all other communications between them relating to the license and to the subject hereof. This Agreement may not be amended except by writing executed by authorized representatives of both parties. No
representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party. 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	19.6	Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United States of America, provide the exclusive forum for any court action between the parties relating to this
Agreement. Forty Seven submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over Forty Seven or constitutes an inconvenient or improper forum. 

 

	19.7	Headings. No headings in this Agreement affect its interpretation. 

  

	19.8	Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used.
The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 

The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. 

 

					
		 	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY	 	
			
		 	Signature: /s/ Katherine Ku                            	 	
		 	Name: Katherine Ku	 	
		 	Title: Executive Director	 	
			
		 	Date:	 	
			
		 	FORTY SEVEN, INC.	 	
			
		 	Signature /s/ Jonathan MacQuitty                    	 	
		 	Name: Jonathan MacQuitty	 	
		 	Title: CEO	 	
			
		 	Date:	 	

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix A - Milestones 

[*] 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix B – Sample Reporting Form 

Stanford Docket No. S- 
 This report is provided pursuant to the
license agreement between Stanford University and (Company Name) 
 License Agreement Effective Date: 

Name(s) of Licensed Products being reported: 
  

					
	 Report Covering Period
	  	 	 
	 Yearly Maintenance Fee
	  	$	            	 
	 Number of Sublicenses Executed
	  			
	 Gross Revenue

U.S. Gross Revenue

Non-U.S. Gross Revenue
	  	$
 $
	
 
	 
  

	 Net Sales

U.S. Net Sales

Non-U.S. Net Sales
	  	$
 $
	
 
	 
  

	 Royalty Calculation
	  			
	 Royalty Subtotal
	  	$		 
	 Credit
	  	$		 
	 Royalty Due
	  	$		 

 Comments: 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix C – Client and Billing Agreement 

The Board of Trustees of the Leland Stanford Junior University (“STANFORD”); and
                     a Corporation of the State
of                    , with a principal place of business at , (“COMPANY”); have agreed to use the law firm of (“FIRM”) to
prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”). 

WHEREAS, FIRM desires to perform the legal services related to obtaining and maintaining the Patents; and 

WHEREAS, STANFORD remains the client of the FIRM; and 
 WHEREAS,
COMPANY is the licensee of STANFORD’s interest in the Patents; 
 NOW THEREFORE, in consideration of the premises and the faithful performance of the
covenants herein contained, IT IS AGREED: 
 1 FIRM can interact directly with COMPANY on all patent prosecution matters related to the Patents and will
copy STANFORD on all correspondence. STANFORD will be notified by FIRM prior to any substantive actions and will have final approval on proceeding with such actions. In addition, as prosecution proceeds, FIRM will notify STANFORD if there is any
change in inventorship from the originally filed application. 
 2 COMPANY is responsible for the payment of all charges and fees by FIRM related to the
prosecution and maintenance of the Patents. FIRM will invoice COMPANY and COMPANY must pay FIRM directly for all charges. If STANFORD requests, STANFORD will be copied on all invoices and payments. FIRM must inform STANFORD within 90 days if the
licensee is delinquent on payment. Otherwise, STANFORD will not be responsible for those expenses. 
 3 Notices and copies of all correspondence should be
sent to the following: 
 To COMPANY: 
 Name,
Title 
 Company Name 
 Address

 To STANFORD: 
 Name 

Office of Technology Licensing 

Stanford University 
 3000 El
Camino Real 
 Building 5, Suite 300 

Palo Alto, CA 94306-2100 
 To FIRM: 

Attorney Name 
 Law Firm Address

 4 The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which
the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
law based solely on the absence of an original signature. 
  

	
	ACCEPTED AND AGREED TO:
	
	STANFORD
	
	By:                                     
                           
	Name: Katharine Ku
	Title: Director
	
	Date:
	
	Company Name
	
	By:                                     
                           
	Name:
	Title:
	
	Date:
	
	Law Firm Name
	
	By:                                     
                           
	Name:
	Title:
	
	Date:

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix D 

Exclusive Patents 
  

							
	 Docket
	  	 Docket Title
	  	 Serial Number
	  	 Issued Patent
Number

	 [*]
	  	[*]	  	[*]	  	[*]

  

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix E 

Licensed Information 
 [*]

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix F 

Licensed Technology 
 [*]

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix G – [*] Sequence 

[*] 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Appendix H – Hu5F9 Sequence 

[*] 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Exhibit 1 – Inventors and Share Allocation - To be provided by Stanford 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 Forty Seven 

April 19, 2017 

Amendment No. 1 to Exclusive (Equity) Agreement 

This Amendment No. 1 (this “Amendment”) to the Exclusive (Equity) Agreement, dated the 19th of November, 2015 (the
“Agreement”) is entered into as of April 19, 2017 (the “Amendment No. 1 Effective Date”) by and between Forty Seven, Inc. (“Forty Seven”) and The Board of Trustees of the
Leland Stanford Junior University (“Stanford”). 
 Background 

A. The parties entered into the Agreement pursuant to which Stanford licensed to Forty Seven certain inventions, patent applications, patents, and
technologies relating to [*]. 
 B. The parties understand that Stanford, pursuant to the Third Party Option Agreement, has granted to one third party an
exclusive option to acquire an exclusive license under the [*] Patents in Third Party [*] Field of Use (each, as defined below). 
 C. The parties agree to
amend the Licensed Field of Use in the Agreement all on the terms and conditions below. The parties also agree to omit the Purchase Right clauses, update the insurances clause, and amend Appendices D, E and F. 

Amendment 
 The parties hereby agree to
amend the Agreement as follows: 
 1. Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to them
in the Agreement. 
 2. Section 2.19 of the Agreement is hereby deleted in its entirety and replaced with the following: 

2.19 “Licensed Field of Use” means (i) with respect to the Exclusive Patents, the Exclusive Field of Use, (ii) with
respect to the SIRPa Component Patents, the field of use outside the SIRPa Component Field of Use, and (iii) with respect to the Limited Exclusive Patents, the Licensed Technology and the Licensed Information, all fields of use. With respect
only to the [*] Patents, Forty Seven acknowledges that the [*] Patents are subject to an option granted to a third party for an exclusive license to the Third Party [*] Field of Use, under an Investigator Sponsored Research Agreement between
Stanford and the third party including the amendment effective February 27, 2017. For clarity, Forty Seven agrees that Stanford is free to grant an exclusive license under this option to the third party to the [*] Patents in the Third Party [*]
Field of Use, in the event the third party exercises its option. 
 (A) “[*] Patents” means any patents and patent
applications that claim priority to provisional [*] under Docket [*]. 
 (B) “Third Party [*] Field of Use” means
the use of [*] for the purpose of [*]. 
 3. Section 2.36 of the Agreement is hereby amended by deleting the defined terms table in its entirety and
replacing it with the following: 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 1 

 

					
	 Term
	  	Section Defined	 
	[*]	  	 	[*]	 
	[*]	  	 	[*]	 
	CIRM	  	 	.l	 
	[*] Patents	  	 	2.19(B)	 
	Claims	  	 	10.l(B)	 
	Deficient Product	  	 	6.4	 
	Disputed Breach Arbitration	  	 	17.1	 
	Effective Date	  	 	Preamble	 
	First Round	  	 	7.3	 
	Forty Seven	  	 	Preamble	 
	Generic Competition	  	 	7.10	 
	HHMI	  	 	l	 
	HHMI License	  	 	3.5	 
	HHMI Patents	  	 	3.5	 

					
	LLS	  	 	1	 
	Ludwig	  	 	l	 
	NIH	  	 	l	 
	NYSCF	  	 	l	 
	SIRPa. Component Patent Matters	  	 	14.l(D)	 
	Stanford	  	 	Preamble	 
	Terminated Patent Rights	  	 	6.4	 
	Third Party [*] Field of Use	  	 	2.19(B)	 
	Third Party License Agreement.	  	 	3.1	 
	Third Party Negotiation Period	  	 	2.19(A)	 
	Third Party Option Agreement	  	 	2.19(A)	 
	Third Party Option Period	  	 	2.19(A)	 
	Triggering Event	  	 	3.1	 

 
 

  

	5.	Section 7.2 of the Agreement is hereby deleted in its entirety and replaced with the following: 

7.2 Equity Interest. As further consideration, Forty Seven will grant to Stanford [*] shares of common stock in Forty Seven. When
issued, those [*] shares of common stock will represent not less than [*]% of the common stock in Forty Seven on a Fully-Diluted Basis. The per share valuation of these shares will be provided to Stanford within [*] days of the Effective Date. Forty
Seven agrees to provide Stanford with the capitalization table upon which the above calculation is made. Forty Seven will issue shares granted to Stanford pursuant to this Section 7.2 and Section 7.3 directly to Stanford. Stanford
acknowledges that, in partial consideration for Forty Seven issuing shares under this Agreement, Forty Seven intends to require inventors to execute inventors certificates certifying that inventors have assigned and do assign their rights in the
Licensed Patents, Licensed Technology, and Licensed Information to Stanford, and disclosing any agreements to which inventor is a party that grant any third party license or ownership in or to any of the Licensed Patents. Except as set forth in the
foregoing sentence, Forty Seven shall not require inventors to execute any additional certification, or otherwise provide any additional representations or warranties, with respect to the Licensed Patents, Licensed Technology, and Licensed
Information. Inventors shall be third party beneficiaries to the foregoing provisions. 
  

	6.	The text of Section 7.4 is hereby deleted in its entirety and replaced with the word “OMITTED”. 

  

	7.	The text of Section 7.5 is hereby deleted in its entirety and replaced with the word “OMITTED”. 

  

	8.	Section 10.4 of the Agreement is hereby deleted in its entirety and replaced with the following: 

10.4 Insurance. Prior to the first testing of a Licensed Product by Forty Seven in a human and thereafter during the term of this
Agreement, Forty Seven will maintain Comprehensive General Liability Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier (except for permitted self-insurance, described below) to cover the
activities of Forty Seven and its sublicensees. The insurance will provide minimum limits of liability of $[*] and will include all Stanford Indemnitees and HHMI Indemnitees as additional insureds. Insurance must cover claims incurred, discovered,
manifested, or made during or after the expiration of this 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 2 

 
Agreement and (except for permitted self-insurance, described below) must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within
[*] days of the Effective Date of this Agreement, Forty Seven will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Forty Seven will provide to Stanford [*] days prior written notice of cancellation
or material change to this insurance coverage. Forty Seven will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for at least the minimum limits set forth above. All insurance of Forty
Seven will be primary coverage; insurance of Stanford Indemnitees and HHMI Indemnitees will be excess and noncontributory. Notwithstanding this Section 10.4 and Section 4.3 above, in any Sublicense between Forty Seven and a third party
that is engaged in the business of selling pharmaceutical products, whose revenues from such sales (on a consolidated basis in the last full fiscal year) was in excess of [*], such third party may self-insure all or any portion of the required
insurance. 
 9. Appendix D of the Agreement is hereby deleted in its entirety and replaced with the Appendix D attached hereto as Schedule 1. 

10. Appendix E of the Agreement is hereby deleted in its entirety and replaced with the Appendix E attached hereto as Schedule 2. Forty-Seven confirms
that Stanford has fulfilled its obligations to provide the Licensed Information under this Amendment. 
 11. Appendix F of the Agreement is hereby
deleted in its entirety and replaced with the Appendix F attached hereto as Schedule 3. Forty-Seven confirms that Stanford has fulfilled its obligations to provide the Licensed Technology under this Amendment. 

12. In consideration for this Amendment No. 1, Forty-Seven will pay Stanford $[*] within [*] days of the Amendment No. 1 Effective Date. 

13. Except as specifically set forth in this Amendment, the terms and conditions of the Agreement shall remain in full force and effect. This Amendment
constitutes the entire agreement among the parties with respect to the amendment of the Agreement, and supersedes all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof. No waiver
of the performance of any obligation under this Amendment shall be effective unless it has been given in writing and signed by the party giving such waiver. No provision of this Amendment may be amended or modified other than by a written document
signed by authorized representatives of each party. 
 14. This Amendment shall be governed by and construed in accordance with the laws of the State
of California, United States of America, without reference to any rules of conflict of laws. 
 {Signatures to follow} 

 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 3 

 The parties execute this Amendment in duplicate originals by their duly authorized officers or representatives.

  

					
		 	 THE BOARD OF TRUSTEES OF THE LELAND

STANFORD JUNIOR UNIVERSITY

			
		 	Signature:	  	 /s/ Katharine Ku

		 	Name:	  	Katharine Ku
		 	Title:	  	Executive Director
			
		 	Date:	  	April 19, 2017
		
		 	FORTY SEVEN, INC.
			
		 	Signature:	  	 /s/ Jonathan MacQuitty

		 	Name:	  	Jonathan MacQuitty
		 	Title:	  	CEO
			
		 	Date:	  	

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 4 

 SCHEDULE 1 

Appendix D 
 Exclusive
Patents 
  

							
	 Docket
	  	 Docket Title
	  	 Serial Number
	  	 Issued Patent

Number

	 [*]
	  	[*]	  	[*]	  	[*]

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 5 

 SCHEDULE2 

Appendix E 
 Licensed
Information 
 [*] 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 6 

 SCHEDULE 3 

Appendix F 
 Licensed
Technology 
 [*] 

  

	[*]	= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 7EX-10.13

 Exhibit 10.13 
  

 
 CONFIDENTIAL 
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Assigned Capacity and Manufacturing Agreement 

(the “Agreement”) 
 by and between 

Lonza Sales AG 
 Münchensteinerstrasse 38 

CH-4002 Basel 

Switzerland 
 - hereinafter
“Lonza” - 
 and 
 Forty Seven Inc., 

1490 O’Brien Drive, Suite A 
 Menlo Park, CA 94025 USA 

- hereinafter “Forty Seven” - 

Effective as of 30th of August, 2016 (the “Effective Date”) 

 

 
 CONFIDENTIAL 
  

 Table of Contents 
  

							
	 	 	 	  	Page	 
	1.	 	 Definitions and Interpretation
	  	 	3	 
			
	2.	 	 Performance of Services
	  	 	8	 
			
	3.	 	 Project Management / Steering Committee
	  	 	10	 
			
	4.	 	 Quality
	  	 	10	 
			
	5.	 	 Insurance
	  	 	11	 
			
	6.	 	 Assigned Capacity, Alternate Product, Forecasting, Ordering and Cancellation
	  	 	11	 
			
	7.	 	 Delivery and Acceptance
	  	 	12	 
			
	8.	 	 Price and Payment
	  	 	14	 
			
	9.	 	 [Intentionally Omitted.]
	  	 	15	 
			
	10.	 	 Intellectual Property
	  	 	15	 
			
	11.	 	 Warranties
	  	 	17	 
			
	12.	 	 Indemnification and Liability
	  	 	19	 
			
	13.	 	 Confidentiality
	  	 	20	 
			
	14.	 	 Term and Termination
	  	 	22	 
			
	15.	 	 Force Majeure
	  	 	23	 
			
	16.	 	 Miscellaneous
	  	 	24	 

  

			
	Appendix A	  	Project Plan
	Appendix B	  	(I) Price and (I) Outline Technology Transfer Terms
	Appendix C	  	Quality Agreement
	Appendix D	  	Specifications
	Appendix E	  	Approved Entities

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2. 

 

 
 CONFIDENTIAL 
  

 Recitals 

WHEREAS, Forty Seven is engaged in the development and research of certain products for the treatment of various indications (as further defined below,
“Products”); 
 WHEREAS, Lonza and its Affiliates have expertise in the evaluation, development and manufacture of such Products; 

WHEREAS, Forty Seven wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement; and 

WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Forty Seven in accordance with the terms and subject to the conditions set out
herein. 
 NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the parties intending to
be legally bound, agree as follows: 
  

	1.	Definitions and Interpretation 

  

			
	“Affiliate”	  	means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party. “Control” means the ownership of more than fifty percent (50%) of
the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.
		
	“Agreement”	  	means this agreement incorporating all Appendices, as amended from time to time by written agreement of the Parties.
		
	“Alternate Product(s)”	  	means any product(s) which the Parties agree may be substituted in place of or manufactured in addition to the CD47 Product in accordance with Clause 6.2, and after such substitution all references in this Agreement to
“Product” shall be deemed to apply to such Alternate Product(s).
		
	“Applicable Laws”	  	means all relevant U.S., U.K. and European Union, federal, state and local laws, statutes, rules, and regulations which are applicable to a Party’s activities hereunder, including, without limitation, the applicable regulations
and guidelines of any Governmental Authority and cGMP together with amendments thereto.
		
	“Assigned Capacity”	  	means the annual capacity at the Facility assigned by Lonza to Forty Seven for the manufacture of cGMP Batches as described in clause 6.1.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3. 

 

 
 CONFIDENTIAL 
  

			
		
	“Background Intellectual Property”	  	means any intellectual Property either (i) owned or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of
this Agreement.
		
	“Batch”	  	means the Product derived from a single run of the Manufacturing Process at the Facility [*] and associated analytical testing required for the release of the Product.
		
	“CD47 Product”	  	means the human IgG antibody produced by the Cell Line, known as SSCI047 that binds to CD47 and of which Forty Seven is the proprietor as set out in Appendix D.
		
	“Cell Line”	  	means the GS-CHO cell line expressing Product, created by Lonza under the Prior MSA, the particulars of which are set out in Appendix D, and which does not include Lonza’s host cell
lines.
		
	“Certificate of Analysis”	  	means a document prepared by Lonza listing tests performed by Lonza or approved External Laboratories, the Specifications and test results.
		
	“Certificate of Compliance”	  	means a document prepared by Lonza: (i) listing the manufacturing date, unique Batch number, and concentration of Product in such Batch, (i¡) certifying that such Batch was manufactured in accordance with the Master Batch
Record and cGMP
		
	“cGMP”	  	means those laws and regulations applicable in the U.S., U.K. and European Union, relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in
the ICH guidelines, including without limitation, ICH Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical ingredients”, US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good
Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC. For the avoidance of doubt, Lonza’s operational quality standards are defined in internal cGMP policy documents.
		
	“cGMP Batches”	  	means any Batches which are required under the Project Plan to be manufactured in accordance with cGMP.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4. 

 

 
 CONFIDENTIAL 
  

			
		
	“Commencement Date”	  	means the date of removal of the vial of cells from frozen storage for the production of a Batch.
		
	“Confidential Information”	  	means Forty Seven Information and/or Lonza Information, as the context requires.
		
	“EMA”	  	means the European Medicines Agency, or any successor agency thereto.
		
	“External Laboratories”	  	means any Third Party instructed by Lonza, with Forty Seven’s prior consent, which is to conduct activities required to complete the Services.
		
	“Facility”	  	means Lonza’s manufacturing facility at Slough, United Kingdom.
		
	“FDA”	  	means the United States Food and Drug Administration, or any successor agency thereto.
		
	“Forty Seven Information”	  	means all technical and other information (i) from time to time supplied by Forty Seven to Lonza under this Agreement which, at the time of disclosure by Forty Seven, was not known to Lonza or in the public domain or
(ii) which was owned by Forty Seven pursuant to the Prior MSA and/or is specific to the Cell Line or Product, or any other materials or information supplied by Forty Seven to Lonza under this Agreement.
		
	“Forty Seven Materials”	  	means any components of Product, or other materials of any nature as may be provided by Forty Seven to Lonza under this Agreement; provided that the Cell Line will be subject always to the terms of the GS Licence.
		
	“Governmental Authority”	  	means any Regulatory Authority and any national, multi-national, regional, state or local regulatory agency, department, bureau, or other governmental entity in the U.S., U.K. or European Union.
		
	“GS Licence”	  	means the licence agreement between the Parties dated 24 May 2016 for the use of Lonza’s proprietary glutamine synthetase gene expression system, as amended by the Parties from time to time.
		
	“Intellectual Property”	  	means (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential
information

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5. 

 

 
 CONFIDENTIAL 
  

			
		  	(including know-how) and any other intellectual property rights, in each case whether registered or unregistered, (ii) all applications (or rights to apply) for, and renewals or
extensions of, any of the rights described in the foregoing sub-clause (i) and (ii) and all rights and applications that are similar or equivalent to the rights and application described in the foregoing sub-clauses (i) and (ii), which exist now, or which come to exist in the future, in any part of the world.
		
	“Lonza Information”	  	means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or any Affiliate of Lonza to Forty Seven under or in
connection with this Agreement, including without limitation, any and all Lonza know-how and trade secrets, but excluding any Forty Seven Information.
		
	“Manufacturing Process”	  	means Lonza’s production process for the manufacture of Product.
		
	“Master Batch Record”	  	means the document, proposed by Lonza and approved by Forty Seven, which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product.
		
	“MHRA”	  	means the Medicines and Healthcare products Regulatory Agency, or any successor agency thereto.
		
	“New Forty Seven Intellectual Property”	  	has the meaning given in Clause 10.2.
		
	“New General Application Intellectual Property”	  	has the meaning given in Clause 10.3.
		
	“Party”	  	means each of Lonza and Forty Seven and, together, the “Parties”.
		
	“Price”	  	means the price for the Services and Products as set out in part I of Appendix B.
		
	“Prior MSA”	  	means the sub-award agreement dated 25 August 2010, as novated and amended by the novation and amendment agreement between the Parties dated 01 March 2016 and as amended by the Parties
from time to time.
		
	“Product(s)”	  	means the CD47 Product and/or the Alternate Product(s) to be manufactured by Lonza under this Agreement.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6. 

 

 
 CONFIDENTIAL 
  

			
		
	“Project Plan”	  	means the plan(s) describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time. The initial Project Plan is attached
hereto as Appendix A.
		
	“Quality Agreement”	  	means the quality agreement, attached hereto as Appendix C, setting out the responsibilities of the Parties in relation to quality as required for compliance with cGMP.
		
	“Raw Materials”	  	means all ingredients, solvents and other components of the Product required to perform the Manufacturing Process or Services set forth in the bill of materials detailing the same [*].
		
	“Raw Materials Fee”	  	means the procurement and handling fee of [*] of the amount incurred by Lonza to be paid to a Third Party (“Lonza’s Cost”) for the acquisition of Raw Materials (other than Resins) that is charged to Forty Seven in
addition to Lonza’s Cost of such Raw Materials.
		
	“Regulatory Approval”	  	means, with respect to a Product, all approvals, licenses, registrations or authorizations necessary for the commercialization of such Product in a particular jurisdiction.
		
	“Regulatory Authority”	  	means the FDA, MHRA, EMA and any other similar regulatory authorities as may be agreed upon in writing by the Parties.
		
	“Release”	  	has the meaning given in Clause 7.1
		
	“Resin”	  	means the chromatographic media and/or UF membranes intended to refine or purify the Product, as specified in the Master Batch Record [*].
		
	“Safety Stock”	  	has the meaning set out in Clause 2.4.
		
	“Services”	  	means all or any part of the services to be performed by Lonza under this Agreement, particulars of which are set out in a Project Plan.
		
	“Specifications”	  	means the specifications of the Product as specified in Appendix D, which may be amended from time to time in accordance with this Agreement.
		
	“Suite Fee”	  	has the meaning set out in Clause 8.1.
		
	“Term”	  	has the meaning given in Clause 14.1.
		
	“Third Party”	  	means any party other than Forty Seven, Lonza and their respective Affiliates.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7. 

 

 
 CONFIDENTIAL 
  

 ln this Agreement references to the Parties are to the Parties to this Agreement, headings are used for
convenience only and do not affect its interpretation, references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any
subordinate legislation made under the statutory provision, references to the singular include the plural and vice versa, and references to the word “including” are to be construed without limitation. 

 

	2.	Performance of Services 

  

	 	2.1	Performance of Services. Subject to clause 2.3, Lonza shall itself and through its Affiliates, diligently carry out the Services at the Facility as provided in the Project Plan and use commercially reasonable
efforts to perform the Services without any material defect and according to the estimated timelines as set forth in the Project Plan (owing to the unpredictable nature of the biological processes involved in the Services, the timescales set down
for the performance of the Services are estimated only). Lonza shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement. Lonza may subcontract or
delegate any of its rights or obligations under this Agreement to perform the Services to its Affiliate(s); provided that Lonza shall be responsible for each such Affiliate’s performance or
non-performance under this Agreement as if Lonza itself were performing such activities. Lonza may engage an External Laboratory to provide some of the Services provided, that any External Laboratories shall
be subject to the same obligations and other provisions contained in this Agreement or any applicable Project Plan. In the event of a dispute Lonza shall use its reasonable endeavours to enforce such obligations upon such External Laboratories and
pass onto the Customer whatever remedies it obtains from such External Laboratories provided always that Lonza shall not be responsible for any services performed by such External Laboratories. 

 

	 	2.2	cGMP Batches. With respect to the cGMP Batches of Product manufactured, it is agreed that Lonza shall manufacture the cGMP Batches of Product to meet the Specification provided that there shall be no obligation
(other than to use commercially reasonable efforts) to meet the Specification in respect of the first [*] cGMP Batches of Product manufactured, or in respect of the first [*] cGMP Batches of Product manufactured following any change in the process
for such Product agreed to or requested by Forty Seven. 

  

	 	2.3	Manufacturing Process. Any changes to the Specifications or the Manufacturing Process for a Product shall be carried out in accordance with the Quality Agreement and Lonza’s standard operating procedures.

  

	 	2.4	Supply of Forty Seven Information and Forty Seven Materials. Forty Seven shall supply to Lonza all Forty Seven Information and Forty Seven Materials, and other information or materials that may be reasonably
required by Lonza to perform the Services. Lonza shall not be responsible for any delays arising out of Forty Seven’s failure to provide such Forty Seven Information, Forty Seven Materials, or other information or materials reasonably required
to perform the Services to Lonza, and [*], including, if applicable, any [*]. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8. 

 

 
 CONFIDENTIAL 
  

	 	2.5	Forty Seven Materials. 

  

	 	2.5.1	Sale or License. All Forty Seven Materials shall remain the property of Forty Seven, and the transfer of physical possession of any such Forty Seven Materials to, and the physical possession of such Forty Seven
Materials by, Lonza, including its Affiliates and/or any External Laboratory shall not be (nor be construed as) a sale, lease, offer to sell or lease, or other transfer of title of such materials to Lonza including its Affiliates and/or any External
Laboratories, provided that the Cell Line shall be subject always to the terms of the GS Licence. 

  

	 	2.5.2	Limited Use. Lonza including its Affiliates and any External Laboratories shall not use the Forty Seven Materials for any purpose other than as necessary for the performance of the Services. Subject to clause
2.1, Lonza, including its Affiliates and any External Laboratories will not provide or transfer any Forty Seven Materials to any Third Party without the prior written consent of the Forty Seven. Lonza, its Affiliates and/or any External Laboratories
shall only use the Forty Seven Materials in accordance with this Agreement and Applicable Laws. 

  

	 	2.5.3	No Modification or Derivation. Lonza, its Affiliates and External Laboratories shall not attempt to alter or modify the Forty Seven Materials in any way, or to make any derivatives or analogs thereof, without the
express prior written consent of Forty Seven, and shall not under any circumstances attempt, directly or indirectly, to analyze, characterize, reverse engineer or otherwise derive the structures, sequences, or constructs of the Forty Seven
Materials. 

  

	 	2.5.4	Care in Use. Subject to clause 2.8, Lonza agrees to use, and shall Cause its Affiliates and External Laboratories to use reasonable care in the use, handling, storage, containment, transportation and disposition
of the Forty Seven Materials. Lonza shall not use, nor authorize the use of, any Forty Seven Materials on or in humans for any purpose under any circumstances. 

  

	 	2.6	Raw Materials. Lonza shall procure all required Raw Materials as well as consumables, other than those Raw Materials that are Forty Seven Materials. Forty Seven shall be responsible for payment in accordance with
this Clause 2.6, Clause 8.5 and Clause 14.3.2(b) for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza in accordance with this Agreement. Upon cancellation of any Batch by Forty Seven, or termination of this
Agreement all such unused Raw Materials shall be paid for by Forty Seven, at the cost incurred by Lonza plus the Raw Materials Fee, within [*] days of invoice and at Forty Seven’s option, either (a) delivered to Forty Seven or
(b) disposed of by Lonza; provided that upon any such cancellation or termination, Lonza shall use commercially reasonable efforts to cancel or mitigate any obligation to purchase Raw Materials. 

 

	 	2.7	Safety Stock. Lonza will, unless Forty Seven instructs Lonza otherwise, and subject to Forty Seven paying the appropriate Raw Materials Fee, maintain a sufficient safety stock of Raw Materials (including a safety
stock of Resin) in accordance with Lonza’s standard policies or as otherwise agreed in writing by the Parties. 

  

	 	2.8	Immediately following the Effective Date, Forty Seven shall supply to Lonza the Forty Seven Information with full details of any hazards relating to the Forty Seven Materials, their storage and use. On review and
approval by Lonza’s safety committee of this Forty Seven Information and the referenced Forty Seven Materials, Forty Seven Background Intellectual Property, and any other necessary Intellectual Property shall be provided to Lonza at
Lonza’s request. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9. 

 

 
 CONFIDENTIAL 
  

	 	2.9	Records. Lonza will maintain in accordance with the Quality Agreement records and samples relating to the manufacture of the Product. 

 

	3.	Project Management / Steering Committee 

  

	 	3.1	Project Plans. With respect to a new project to be governed by this Agreement, a new Project Plan shall be added by agreement in a writing signed by the Parties and appended to Appendix A. Each Project Plan shall
include a description of the Services to be provided, the Product to be manufactured, Specifications, a schedule for completion of the Project Plan, pricing details, and such other information as is necessary for relevant Services. ln the event of a
conflict between the terms of a Project Plan and this Agreement, the terms of this Agreement will govern unless the Parties expressly agree otherwise in writing. Any modifications or amendments to the Project Plans shall be expressly agreed in
writing and signed by the Parties 3.2 Project Management. With respect to each Project Plan, each party will appoint a project manager who will be the party responsible for overseeing the Project Plan. 

 

	 	3.2	Steering Committee. Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the
Parties. ln the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Forty Seven and Lonza. 

The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues
arising under this Agreement. ln addition to the primary function described above, the Steering Committee shall also take on the following responsibilities: 
  

	 	3.2.1	discuss and seek resolution of issues around management of the Services; 

  

	 	3.2.2	agree and monitor deadlines and milestones for the Services; 

  

	 	3.2.3	discuss and seek resolution for any Batch failures and unreleased Batches; and 

  

	 	3.2.4	discuss and recommend any changes to the Services (although such changes will not take effect until they have been incorporated into a written amendment to the Project Plan which has been signed by the Parties).

  

	 	3.3	Person in Plant. Forty Seven shall be permitted to have, at no additional cost, [*] at the Facility as reasonably requested by Forty Seven, at any time during the Manufacturing Process for the purpose of
observing, reporting on, and consulting as to the performance of the Services. Such employee shall be subject to and agree to abide by confidentiality obligations to Third Parties and Lonza’s customary practices and operating procedures
regarding persons in plant, and such employee agrees to comply with all instructions of Lonza’s employees at the Facility. 

  

	4.	Quality 

  

	 	4.1	Responsibility for quality assurance and quality control of Product shall be allocated between Forty Seven and Lonza as set forth in the Quality Agreement and in Lonza standard operating procedures. If there is a
conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail. If the Quality Agreement is not in place at the Effective Date, Lonza and Forty Seven commit to enter
into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing under this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10. 

 

 
 CONFIDENTIAL 
  

	 	4.2	Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement. 

  

	5.	Insurance 

  

	 	5.1	Each Party shall, during the Term and for [*] years after delivery of the last Product manufactured or Services provided under this Agreement, obtain and maintain at its own cost and expense from a qualified insurance
company, comprehensive general liability insurance including, but not limited to, contractual liability coverage and product liability coverage in the amount of at least [*] per claim. Each Party shall provide the respective other Party with a
certificate of such insurance upon reasonable request. 

  

	6.	Assigned Capacity, Alternate Product, Forecasting, Ordering and Cancellation 

  

	 	6.1	Assigned Capacity. 

  

	 	(a)	Lonza shall manufacture [*] cGMP Batches during the Assigned Capacity. Lonza will use commercially reasonable efforts to accommodate Forty Seven’s Forecast as set out in clause 6.3 below, provided however that,
except as expressly set forth in this Agreement (including Section 6.1(b)), [*] and subject to [*], Lonza shall [*]. 

  

	 	(b)	Whether a cGMP Batch is manufactured within the Assigned Capacity shall be measured from the Commencement Date of such cGMP Batch and for the purposes of clarity, such Assigned capacity shall be (a) from [*] to [*]
at [*] çGMP Batches at [*] scale at Lonza’s Facility and (b) from [*] until [*] al [*] cGMP Batches at [*] scale per calendar year at Lonza’s Facility. Notwithstanding any provision to the contrary herein, Lonza shall
manufacture the first cGMP Batch within the Assigned Capacity in [*] and Lonza shall not manufacture more than [*] cGMP Batches in any calendar quarter unless otherwise agreed in writing between the Parties. Subject to the foregoing provisions, the
above cGMP Batches shall be regarded as a binding commitment on the Parties for the Term, and (except as set forth in Clauses [*]) [*]. 

  

	 	6.2	Alternate Product. Forty Seven may request Lonza to manufacture Alternate Product(s) in place of or in addition to the CD47 Product within the Assigned Capacity provided always that any such Alternate Products
does not exceed Lonza’s then current standard processing times and subject to Lonza’s agreement, and the negotiation and execution of an amended Project Plan agreed between the Parties that shall set out the price and terms for the
transfer of the Alternate Product into the Facility and for payment of all such additional costs as reasonably incurred by Lonza in the completion of such transfer. If an Alternate Product is introduced, the number of cGMP Batches to be manufactured
within the Assigned Capacity in each year may be revised as agreed in writing by the Parties. 

  

	 	6.3	Forecasting. No later than the first (1st) day of each calendar quarter, Forty Seven shall supply Lonza with a written forecast showing Forty Seven’s good faith estimated quarterly Commencement Date
requirements for cGMP Batches to be manufactured within the Assigned Capacity in the following [*] month period (the “Forecast”) provided that in no event shall more than [*] such Batches per year be forecast. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11. 

 

 
 CONFIDENTIAL 
  

	 	6.4	Rescheduling. Except as set forth in Clause 7.3.3 and subject to Clause 6.1, [*] reschedule the Commencement Date with respect to any cGMP Batch. 

 

	 	6.5	Cancellation of cGMP Batches. If Forty Seven cancels any cGMP Batch it shall not receive any refund or rebate of the Suite Fee (except as set forth in this Clause 6.5 or Clause 6.7). In addition, Forty Seven
shall pay for all costs associated with the cancelled cGMP Batch that Lonza has incurred, or is irrevocably committed to pay, including the costs of Raw Materials and the Raw Materials Fee, in accordance with Clause 2.6. Lonza shall use commercially
reasonable efforts to sell all or any part of the Assigned Capacity that Forty Seven has notified Lonza that it does not wish to use, but Lonza does not make any commitment, warranty or representation that it will be successful in finding any Third
Party customer (existing or new) to fill such excess Assigned Capacity. If Lonza is able to sell all or any part of such excess Assigned Capacity to a Third Party, Lonza shall refund to Forty Seven [*] the Suite Fee for such year with respect to
each manufacturing slot Lonza is able to sell to a Third Party. In addition, Forty Seven may refer potential Third Party customers to Lonza in respect of any such excess Assigned Capacity, provided that Lonza shall at all times have the sole and
absolute discretion whether or not it decides to enter into discussions with such referred Third Party customers. 

  

	 	6.6	In the event that the parties agree any additional stages of work to be added to the Project Plan (“Additional Work”), the prices for such Additional Work shall be calculated based on Lonza’s standard
pricing at the time of agreement on such Additional Work. Once the Additional Work has been added into this Agreement, the pricing for such Additional Work shall be subject to review in accordance with the provisions of Clause 8.4.

  

	 	6.7	Scale Up: lf Forty Seven is able to secure a minimum of [*] scale manufacturing cGMP Batch with Lonza (subject to availability) through contractually binding commitment then Lonza will release Forty Seven for [*]
and the [*]; provided that a notice for such change must be given by Forty Seven at least [*]. 

  

	7.	Delivery and Acceptance 

  

	 	7.1	Delivery. All Product shall be delivered [*] (as defined by lncoterms@2010) [*]. Lonza shall deliver to Forty Seven the Certificate of Analysis, the Certificate of Compliance and such other documentation as is
reasonably required to meet all applicable regulatory requirements of the Governmental Authorities not later than the date of delivery of Batches (the “Release”). With respect to any Forty Seven Materials title and risk of loss shall [*]
and with respect to the Product, title and risk of loss shall transfer to Forty Seven upon Release in accordance with this provision. For the avoidance of doubt, shipping or transportation of the Products, whether or not any arrangements are made by
Lonza on behalf of the Forty Seven, shall be made at the sole risk and expense of the Forty Seven. 

  

	 	7.2	Storage. 

  

	 	7.2.1	 Forty Seven shall arrange for shipment and take delivery of each Batch from the Facility, at Forty Seven’s
expense, within [*] days after Release or pay applicable storage costs. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [*] days; provided that any additional storage beyond [*] days will be subject to
availability and, if available, will be charged to Forty Seven and will be subject to a separate agreement. ln addition to clause 8.2, Forty Seven shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import,
duties and fees of 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12. 

 

 
 CONFIDENTIAL 
  

	 	
whatever nature imposed as a result of any storage (other than taxes on Lonza’s income). Notwithstanding anything to the contrary contained in this Agreement, in no event shall Lonza be
required to store any Batch for more than [*] calendar days after Release. Within [*] days following a written request from Lonza, Forty Seven shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of
each stored Batch. 

  

	 	7.2.2	The Products shall be stored by Lonza at Lonza’s premises in accordance with Lonza’s standard operating procedures, subject always to audit by Forty Seven in accordance with the Quality Agreement, and clause
7.2.1. Lonza shall keep all such Products and Forty Seven Materials free of all security interests, liens and other encumbrances and Lonza shall retain control thereof and shall not transfer the same to any Third Party unless otherwise agreed in
writing by the Parties. 

  

	 	7.3	Acceptance/Rejection of Product. 

  

	 	7.3.1	Promptly following Release of cGMP Batches, Forty Seven shall inspect such cGMP Batches and shall have the right to test such Batches to determine compliance with the Specifications. Forty Seven shall notify Lonza in
writing of any rejection of a cGMP Batch based on any claim that it fails to meet Specifications within [*] days of Release, after which time all unrejected cGMP Batches shall be deemed accepted, subject to Forty Seven’s right to reject any
cGMP Batch for latent defects set out in this clause 7.3.1. Forty Seven shall inform Lonza in writing in case of latent defects (i.e. not discovered by routine quality control means), promptly upon discovery of such defects but no later than [*]
after delivery of the Product. 

  

	 	7.3.2	ln the event that Lonza believes that a cGMP Batch has been incorrectly rejected by Forty Seven, Lonza must notify Forty Seven in writing within [*] days (such notice, the “Dispute Notice”) and Lonza may
require that Forty Seven provide to it cGMP Batch samples for testing. Lonza may retain and test the samples of such cGMP Batch. ln the event of a discrepancy between Forty Seven’s and Lonza’s test results such that Lonza’s test
results determine that the cGMP Batch conforms with the Specifications, or there otherwise exists a dispute between the Parties over whether such cGMP Batch fails to conform to the Specifications or the extent to which such failure is attributable
to a given Party, the Parties shall use good faith efforts to resolve any such discrepancy or dispute; provided that if such dispute cannot be settled within [*] days from the receipt of the Dispute Notice, then the Parties will submit a sample of
the cGMP Batch to an independent laboratory and require the independent laboratory promptly to review records, test data and perform comparative tests and/or analyses on samples of the Product that allegedly fails to conform to Specifications. Such
independent laboratory shall be mutually agreed upon by the Parties. The independent laboratory’s results shall be in writing and shall be final and binding save for manifest error. Unless otherwise agreed to by the Parties in writing, the
costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules. 

  

	 	7.3.3	 Subject to clause 2.2, in the event that it is determined (by the Parties or the independent laboratory) that any
cGMP Batch failed to conform with the Specifications (each a “Failed Batch”) and such failure was [*] (“Lonza Responsibility”) then Lonza shall replace such Failed Batch at its sole cost and expense, including bearing the cost of
obtaining any Raw Material, Resin or 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13. 

 

 
 CONFIDENTIAL 
  

	 	
other material required for the manufacture of such replacement cGMP Batch. Such replacement shall be made as promptly as practicable, subject to available manufacturing capacity after the
confirmation of Lonza Responsibility and in any case as soon as reasonably possible after confirmation of Lonza Responsibility. [*] acknowledges and agrees that [*] with respect to a Failed Batch that is a Lonza Responsibility [*], and in
furtherance thereof, [*]. Lonza shall not be responsible for the cost of Raw Materials or Forty Seven Materials consumed in any Batch which failed to meet Specifications except to the extent set forth in this Clause 7.3.3. 

 

	8.	Price and Payment 

  

	 	8.1	Signature Fee and Suite Fee. Forty Seven shall pay a non-refundable signature fee of [*] upon signing this Agreement (“Signature Fee”). In addition to the
Signature Fee, Forty Seven shall pay Lonza an annual Suite Fee of [*]. Except as set forth under this Agreement, the Suite Fee is payable in full regardless of utilization by Forty Seven and the Suite Fee shall not be reduced or refunded if Forty
Seven does not make full use of the Assigned Capacity. 

  

	 	8.2	Other Services. ln addition to Clause 8.1, pricing for the Services (other than the manufacture of Batches within the Assigned Capacity) provided by Lonza are set out in, and based on the assumptions and
information set out in, the applicable Project Plan. In the event of changes to the Services based on Forty Seven’s request which result in additional costs, the Parties shall execute a written amendment to this Agreement. 

 

	 	8.3	Raw Materials, Resins, Raw Materials Fees and Safety Stock. In addition to the Suite Fee in accordance with Clause 8.1, and the prices payable under Clause 8.2, Forty Seven shall pay for all Raw Materials,
Resins, Safety Stock and the Raw Materials Fee. 

  

	 	8.4	Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value added tax (VAT) and of any other applicable taxes, levies, import, duties and fees of whatever nature imposed by or under the
authority of any government or public authority and all such charges applicable to the Services (other than taxes on Lonza’s income) shall be paid by Forty Seven. When sending payment to Lonza, the Forty Seven shall quote the relevant invoice
number in its remittance advice. 

  

	 	8.5	Payment Terms. 

  

	 	8.5.1	Signature Fee and Suite Fee. The Signature Fee shall be immediately payable by the Forty Seven upon signing this Agreement. The Suite Fee shall be payable in [*] instalments each year, with the first payment due
on [*] and the second payment due on [*] and thereafter payable [*] during the Term. Subject to clause 14, Forty Seven will pay the Suite Fee to Lonza for the Term of this Agreement. 

 

	 	8.5.2	Raw Materials and Raw Materials Fee. Lonza’s Cost for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each such Batch. Lonza will provide a list of the Raw
Materials and the unit price reflecting Lonza’s Cost for each component of the Raw Materials (excluding any Lonza Intellectual Property). Resins shall be invoiced at Lonza’s Cost for such Resins [*]. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14. 

 

 
 CONFIDENTIAL 
  

	 	8.5.3	All invoices are strictly net and payment must be made within [*] days of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim.

  

	 	8.6	lf in default of payment of any undisputed invoice on the due date, interest shall accrue on any amount overdue at the lesser of (i) rate of [*] above the London Interbank Offered Rate (LIBOR) or (ii) the
maximum rate allowable by applicable law, interest to accrue on a day to day basis until full payment; and Lonza shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the
Services and or delivery of Product until all overdue amounts have been paid in full including interest for late payments. 

  

	 	8.6.1	Price adjustments. Not more than once per calendar year and with effect from [*], Lonza may adjust the Price for Services in accordance with [*] based upon any change in the index from the previous calendar year
or increase the Price by [*], by providing Forty Seven [*] days prior written notice of such adjustment. The new Price reflecting such Price adjustment shall be effective for any Services and/or Batch for which the Commencement Date is on or after
the effective date of Lonza’s notice to Forty Seven of the Price adjustment. 

  

	 	8.6.2	ln addition to the above, the Price may be changed by Lonza not more than once per calendar year, upon prior written notice to Forty Seven (providing reasonable detail in support thereof), to reflect an increase of more
than [*] (based on the initial Price or any previously amended Price) in Lonza’s costs to manufacture the Product (other than any change in the cost of Raw Materials), including any change in an environmental, safety or regulatory standard that
is outside of Lonza’s control and substantially impacts Lonza’s cost and ability to perform the Services. Notwithstanding the foregoing, in no event shall the Price be increased by more than [*] for the purposes of this clause 8.6.2 in any
calendar year. 

  

	9.	[Intentionally Omitted.] 

  

	10.	Intellectual Property 

  

	 	10.1	Background Intellectual Property. Neither Party will, as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other Party or any of its Affiliates.

  

	 	10.2	New Forty Seven Intellectual Property. Subject to Clauses 10.1 and 10.3, Forty Seven shall own all right, title, and interest in and to any and all Intellectual Property that Lonza and/or its Affiliates, the
External Laboratories or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with Forty Seven or others as a result of the receipt of the Forty Seven Information, Forty Seven
Materials and/or any Products (collectively, the “New Forty Seven Intellectual Property”). For avoidance of doubt, “New Forty Seven Intellectual Property” shall include any material, processes or other items that solely embody,
or that solely are claimed or covered by, any of the foregoing Intellectual Property, but excluding any New General Application Intellectual Property. Lonza shall, and shall cause its Affiliates to, promptly disclose to Forty Seven in writing all
New Forty Seven Intellectual Property. 

  

	 	10.3	 New General Application Intellectual Property. Notwithstanding clause 10.2 and subject to the license
granted in Clause 10.5, Lonza shall own all right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15. 

 

 
 CONFIDENTIAL 
  

	 	
contractors or agents of Lonza, solely or jointly with Forty Seven, develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services (i) that
is generally applicable to the development or manufacture of chemical or biological products or product components and not specific to the Product and the use or practice of which would not require the use or disclosure of Forty Seven Information,
Forty Seven Materials or Forty Seven Background Intellectual Property or (ii) is an improvement of, or direct derivative of, any Lonza Background Intellectual Property and/or Lonza Information (collectively the “New General Application
Intellectual Property”). For avoidance of doubt, “New General Application Intellectual Property” shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual
Property. 

  

	 	10.4	Assignment of New Forty Seven Intellectual Property. Lonza hereby assigns, and shall cause its Affiliates to assign, to Forty Seven all of its right, title and interest in any New Forty Seven Intellectual
Property. Lonza shall execute, and shall cause its personnel as well as its Affiliates, External Laboratories or other contractors or agents and their personnel involved in the performance of the Services to execute, any documents reasonably
required to confirm Forty Seven’s ownership of the New Forty Seven Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New Forty Seven Intellectual Property. This clause 10.4
shall be subject to the terms of the Prior MSA and the GS Licence. Subject to the terms and conditions as set forth in this Agreement and the GS Licence, the Cell Line (excluding any Lonza Background Intellectual Property and New General Application
Intellectual Property), shall be the sole and exclusive property of Forty Seven, and Lonza hereby assigns to Forty Seven all of its right, title and interest in and to the Cell Line. 

 

	 	10.5	Subject to the terms and conditions set forth herein, Lonza hereby grants to Forty Seven a non-exclusive, world-wide, fully paid-up,
irrevocable, transferable license, including the right to grant and authorize sublicenses, under the New General Application Intellectual Property (a) to make, have made, use, sell, offer for sale and import the Products manufactured under this
Agreement and (b) to the extent necessary to practice and exploit Forty Seven’s rights in and to the New Forty Seven Intellectual Property in the Products. 

 

	 	10.6	Forty Seven hereby grants Lonza the non-exclusive right to use the Forty Seven Information, Forty Seven Background Intellectual Property, Forty Seven Materials, New Forty Seven
Intellectual Property, the Cell Line, and any and all other intellectual property supplied by or on behalf of the Forty Seven, during the Term solely for the purpose of fulfilling its obligations under this Agreement. 

 

	 	10.7	ln the event that Forty Seven is not in breach of clause 11.2 and clause 13 and provided that Lonza has not terminated this Agreement pursuant to clause 14.2, Forty Seven will have the right to transfer the
Manufacturing Process to itself and/or any Third Party [*]; provided, however, to the extent such technology transfer includes Lonza Confidential Information, Lonza Background Intellectual Property or New General Application Intellectual Property,
such technology transfer shall be subject to the terms of a technology transfer agreement between the Parties (“Technology Transfer Agreement”) in accordance with the outline terms set out in part II of Appendix B, including the price and
payment terms set forth therein. Lonza shall provide reasonably necessary documents and reasonably cooperate with Forty Seven to complete such technology transfer. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16. 

 

 
 CONFIDENTIAL 
  

	11.	Warranties 

  

	 	11.1	Lonza warrants that: 

  

	 	11.1.1	the Services shall be performed in accordance with this Agreement (including all Appendices hereto) and Applicable Laws; 

  

	 	11.1.2	subject to the provisions set out in clause 2.2 and clause 7.3.3, the manufacture of Product shall be performed in accordance with Applicable Law and cGMP and the Products will, at the date of delivery, meet the
Specifications; 

  

	 	11.1.3	to the best of Lonza’s knowledge and as on the Effective Date of this Agreement, the use by Lonza of the Manufacturing Process will not infringe any rights (including without limitation any intellectual or
industrial property rights) vested in any Third Party, and Lonza will not knowingly include in the Manufacturing Process any elements that infringe any such intellectual or industrial property rights vested in any Third Party; provided however that
Lonza gives no warranty that the use by Lonza including its Affiliates of the Manufacturing Process in association with Forty Seven Materials and/or Forty Seven Information in undertaking the Services shall not infringe any Third Party intellectual
or industrial property rights; 

  

	 	11.1.4	it or its Affiliate holds all necessary permits, approvals, consents and licenses to enable it or such Affiliate to perform the Services to be performed by it or such Affiliate, as applicable, at the Facility (subject
always to Clause 11.2.3) or such other Lonza facility where the Parties may agree in writing that Product may be manufactured; 

  

	 	11.1.5	it has the necessary corporate authorizations to enter into and perform this Agreement; 

  

	 	11.1.6	as on the Effective Date of this Agreement, Lonza including its Affiliates have not been debarred by a Regulatory Authority nor have debarment proceedings against Lonza including its Affiliates been commenced. Lonza
will promptly notify Forty Seven in writing if any such proceedings have commenced or if Lonza including its Affiliates is debarred by a Regulatory Authority. ln the event that Forty Seven receives such notice from Lonza or otherwise becomes aware
that Lonza including its Affiliates is debarred by a Regulatory Authority, then Forty Seven shall have the right to terminate this Agreement in accordance with clause 14.2.1 and in such an event the Forty Seven shall pay to Lonza of all accrued and
unpaid obligations up to the date of termination, to the extent not previously been paid by Forty Seven; 

  

	 	11.1.7	title to all Product shall pass to Forty Seven as set forth in Clause 7.1 free and clear of any security interest, lien or other encumbrance in favour of Lonza; and 

 

	 	11.1.8	each employee of Lonza, a Lonza Affiliate and/or each External Laboratory who will receive or have access to Forty Seven Information or who will perform services will be subject to written obligations (i) to assign
to Lonza any and all right, title and interest in and to all Intellectual Property developed by such employee or External Laboratory in connection with the performance of services in accordance with this Agreement and (ii) to protect the Forty
seven Information in accordance with terms at least as protective of the Forty seven Information as the terms of this Agreement, in each case prior to the earlier of any disclosure of Forty Seven Information to such employee or External Laboratory
or the commencement of any such performance by such employee or External Laboratory. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17. 

 

 
 CONFIDENTIAL 
  

	 	11.2	Forty Seven warrants that: 

  

	 	11.2.1	to the best of the Forty seven’s knowledge, Forty Seven has all the rights necessary to permit Lonza and its Affiliates to perform the Services in accordance with the terms of this Agreement without infringing the
Intellectual Property rights of any Third Party; 

  

	 	11.2.2	Forty Seven will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third Party that Forty Seven Information and/or Forty Seven Background Intellectual Property, Forty Seven
Materials, New Forty Seven Intellectual Property, the Cell Line, and/or any and all other information, materials and Intellectual Property supplied by or on behalf of the Forty Seven, or that the use by Lonza thereof for the provision of the
Services infringes any Intellectual Property or other rights of any Third Party; 

  

	 	11.2.3	to the best of Forty Seven’s knowledge, Forty Seven has all the rights necessary to provide, and permit Lonza and its Affiliates and the External Laboratories to use for the purposes of this Agreement, the Forty
Seven Information, Forty Seven Background Intellectual Property, Forty Seven Materials, New Forty Seven Intellectual Property, the Cell Line (subject to the terms of the GS Licence) and any and all other information, materials and Intellectual
Property supplied by or on behalf of the Forty Seven, and that the use of anything referred to in this clause 11.2.3 will not infringe the Intellectual Property rights of any Third Party; and 

 

	 	11.2.4	Forty Seven has the necessary corporate authorizations to enter into this Agreement. 

  

	 	11.2.5	as on the Effective Date of this Agreement, Forty Seven including its Affiliates have not been debarred by a Regulatory Authority nor have debarment proceedings against Forty Seven including its Affiliates been
commenced. Forty Seven will promptly notify Lonza in writing if any such proceedings have commenced or if Forty Seven including its Affiliates is debarred by a Regulatory Authority. 

 

	 	11.3	DISCLAIMER: THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES, AND ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

	12.	Indemnification and Liability 

  

	 	12.1	 Indemnification by Lonza. Lonza shall indemnify the Forty Seven, its Affiliates, and their respective
officers, employees and agents (“Forty Seven Indemnitees”) for any loss, damage, costs, liability and expenses (including reasonable attorney fees) that Forty Seven Indemnitees may suffer as a result of any Third Party claim arising
directly out of (i) any material breach of the warranties given by Lonza in Clause 11.1 above and/or (ii) any claims alleging that the Services (excluding use by Lonza, Lonza’s Affiliates, contractors or the External Laboratories of
the Forty Seven Information, Forty Seven Background Intellectual Property, Forty Seven Materials, New Forty Seven Intellectual property, and/or any and all information, materials and other Intellectual

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 18. 

 

 
 CONFIDENTIAL 
  

	 	
Property supplied by or on behalf of the Forty Seven (excluding Lonza’s host cell lines)) infringe any Intellectual Property rights of a Third Party except, in each case, to the extent that
such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Forty Seven Indemnitees. 

  

	 	12.2	Indemnification by Forty Seven. Forty Seven shall indemnity Lonza, its Affiliates, and their respective officers, employees and agents (“Lonza Indemnitees”) from and against any loss, damage, costs,
liability and expenses (including reasonable attorney fees) that any Lonza Indemnitees may suffer as a result of any Third Party claim arising directly out of (i) any material breach of the warranties given by Forty Seven in Clause 11.2 above;
and/or (ii) any claims alleging that the performance of Services infringes any Intellectual Property rights of third parties; and/or (iii) the manufacture, use, sale, or distribution by or on behalf of any Forty Seven Indemnitee of any
Product, including any claims of product liability; and/or (iv) the use by Lonza, any of Lonza’s Affiliates, or any External Laboratory in accordance with this Agreement of any Forty Seven Information, Forty Seven Materials, Forty Seven
Background Intellectual Property, New Forty Seven Intellectual Property and/or any other information, materials or Intellectual Property provided by or on behalf of Forty Seven for the purposes of this Agreement (excluding Lonza’s host cell
lines); except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Lonza Indemnitees. 

 

	 	12.3	Indemnification Procedure. lf the Party to be indemnified intends to claim indemnification under this Clause 12, it shall promptly notify the indemnifying Party in writing of such claim. The indemnitor shall have
the right to control the defense and/or settlement thereof; provided, however, that the indemnitor must obtain the prior written consent of the indemnitee (not to be unreasonably withheld) before entering into any settlement of such Third Party
claim that admits fault, wrongdoing or damages (to the extent not readily payable by the indemnitor at the time of settlement) and any indemnitee shall have the right to retain its own counsel at its own expense. The indemnitee, its employees and
agents, shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12. The failure to deliver prompt written notice to the indemnitor of any claim, to the extent prejudicial to its ability to defend
such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12. 

  

	 	12.4	DISCLAIMER OF CERTAIN DAMAGES. SUBJECT ALWAYS TO CLAUSE 12.6 IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER PARTY AND/OR ANY OF THE OTHER PARTY’S AFFILIATES AND/OR ANY OF THE
OTHER PARTY’S INDEMNITEES (IN EACH CASE WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE HOWSOEVER ARISING) FOR ANY LOSS OF PROFITS, LOSS OF REVENUES, LOSS OF GOODWILL, LOSS OF REPUTATION, OR FOR ANY INCIDENTAL,
INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL LOSSES OR DAMAGES, ARISING FROM OR RELATED TO THIS AGREEMENT, PROVIDED THAT THIS SHALL NOT PRECLUDE ANY CLAIM BY LONZA FOR ANY UNPAID INVOICES. 

 

	 	12.5	LIMITATION OF LIABILITY. SUBJECT ALWAYS TO CLAUSE 12.6, THE AGGREGATE LIABILITY OF EACH PARTY AND ITS AFFILIATES TO THE OTHER PARTY AND ITS AFFILIATES WITH RESPECT TO ANY CLAIM UNDER OR IN RELATION TO THIS
AGREEMENT (WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, UNDER ANY INDEMNITY OR OTHERWISE HOWSOEVER ARISING) SHALL NOT EXCEED, IN THE AGGREGATE, [*]. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 19. 

 

 
 CONFIDENTIAL 
  

	 	12.6	NOTHING IN THIS AGREEMENT SHALL OPERATE SO AS TO EXCLUDE OR IN ANY WAY LIMIT A PARTY’S, OR ITS AFFILIATE’S, LIABILITY (i) FOR FRAUD, INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE, OR (ii) FOR DEATH OR
PERSONAL INJURY CAUSED BY ITS FRAUD, INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OR (iii) FOR ANY OTHER LIABILITY THAT MAY NOT BE EXCLUDED OR LIMITED AS A MATTER OF LAW. 

 

	13.	Confidentiality 

  

	 	13.1	A Party receiving Confidential Information (the “Receiving Party”) agrees to strictly keep secret any and all Confidential Information received during the Term from or on behalf of the other Party (the
“Disclosing Party”) as well as the terms of this Agreement using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at least commercially reasonable and customary efforts.
Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to the Receiving Party, observed by the Receiving Party or its employees, agents,
consultants, or representatives, or otherwise learned by the Receiving Party under this Agreement, which the Receiving Party knows or reasonably should know is confidential or proprietary. For the avoidance of doubt, Forty Seven shall be deemed the
Disclosing Party with respect to Forty Seven Information and Lonza shall be deemed the Disclosing Party with respect to Lonza Information. 

  

	 	13.2	Notwithstanding the foregoing, Receiving Party may disclose to any courts and/or other authorities Confidential Information which is or will be required pursuant to applicable governmental or administrative or public
law, rule, regulation or order. ln such case the Party that received the Confidential Information will, to the extent legally permitted, inform the other Party promptly in writing and cooperate with the Disclosing Party in seeking to minimize the
extent of Confidential Information which is required to be disclosed to the courts and/or authorities. If the Disclosing Party fails to obtain any protective order or other remedy, the Receiving Party shall furnish only that portion of the
Confidential Information that is legally required to be disclosed and any Confidential Information so disclosed shall be treated as confidential for all purposes other than such legally compelled disclosure. 

 

	 	13.3	The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information, which: 

  

	 	13.3.1	at the time of disclosure was publicly available; or 

  

	 	13.3.2	is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party; or 

  

	 	13.3.3	as the Receiving Party can establish by competent proof, was rightfully in its possession at the time of disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party (or anyone for
whom it is responsible); or 

  

	 	13.3.4	is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to Disclosing Party or any other party; or 

 

	 	13.3.5	is developed by the Receiving Party independently from and without use of or reference to the Confidential Information, as evidenced by contemporaneous written records. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 20. 

 

 
 CONFIDENTIAL 
  

	 	13.4	The Receiving Party will use Confidential Information of the Disclosing Party only for the purposes of exercising its rights and fulfilling its obligations under this Agreement and will not otherwise make any use of the
Confidential Information of the Disclosing Party for its own separate benefit or the benefit of any Third Party including, without limitation, with respect to research or product development or any reverse engineering or similar testing. The
Receiving Party agrees to return or destroy promptly (and certify such destruction) on Disclosing Party’s request all Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the
Receiving Party in its confidential files for record keeping purposes only. 

  

	 	13.5	Each Party will restrict the disclosure of Confidential Information of the other Party to such officers, employees, professional advisers, consultants, and actual finance-providers of itself and its Affiliates
(“Representatives”) who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information solely for the purpose of this Agreement; provided that each Party may disclose
the terms of this Agreement to potential finance-providers, acquirers and sublicensees in connection with an applicable financing or acquisition of or sublicense by such Party. Prior to disclosure to such persons, the Party in receipt of the
Confidential Information shall bind its and its Affiliates’ Representatives, potential finance provider, potential acquirer and/or potential sublicensee (as applicable) to confidentiality and non-use
obligations no less stringent than those set forth herein and shall be fully responsible and liable for all acts and omissions of such persons in violation of this Clause 13. The Receiving Party shall notify the Disclosing Party as promptly as
practicable of any unauthorized use or disclosure of the Confidential Information. Lonza may disclose Forty Seven’s Confidential Information to Lonza’s Affiliates and the External Laboratories, in each case who have a need to know such
Confidential Information for the purposes of this Agreement and who are bound by written confidentiality and non-use obligations no less protective than those set forth herein. 

 

	 	13.6	The Receiving Party shall at any time be fully liable for any and all breaches of the confidentiality obligations in this Clause 13 by any of its Affiliates or the employees, consultants and representatives of itself or
its Affiliates 

  

	 	13.7	Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided under this Clause 13 by a Party may cause irreparable harm to the other Party and that money
damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach. In the event of any breach and/or threatened breach, then, in addition to all other remedies
available at law or in equity, the non-breaching party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the non-breaching Party.

  

	14.	Term and Termination 

  

	 	14.1	Term. This Agreement shall commence on the Effective Date and shall end on the later of the completion of the final cGMP Batch to be manufactured within the Assigned Capacity or the fifth (5th) anniversary of the Effective Date in 2021 unless terminated earlier as provided herein or extended by mutual written consent of the Parties or otherwise in accordance with the terms of this
Agreement (the “Term”). The Term may be extended by Forty Seven at its sole option and discretion for a further period of one (1) year by providing written notice of such extension to Lonza, such notice shall be provided no later than
[*] and the Parties shall execute a written amendment for such extension. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 21. 

 

 
 CONFIDENTIAL 
  

	 	14.2	Termination. This Agreement may be terminated as follows 

  

	 	14.2.1	by either Party if the other Party breaches a material provision of this Agreement or a Project Plan and fails to cure such breach to the reasonable satisfaction of the
non-breaching Party within [*] days ([*] days for non-payment) following written notification of such breach from the
non-breaching party to the breaching party; provided, however, that such [*] day period shall be extended as agreed by the Parties if the identified breach is incapable of cure within [*] days and if the
breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure (it being understood that this extended period shall be unavailable for any breach regarding non-payment); 

  

	 	14.2.2	by either Party, immediately, if the other Party enters into administration, is declared insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against
it, a petition in bankruptcy or has an administrator or receiver appointed for a substantial part of its assets; 

  

	 	14.2.3	by either Party pursuant to Clause 15; 

  

	 	14.2.4	by Customer for any reason upon providing a written notice of no less than [*] to Lonza. 

  

	 	14.3	Consequences of Termination. ln the event of termination of this Agreement and subject to always to Clauses 8.5,14.4 and 14.5: 

 

	 	14.3.1	all Batches scheduled or in-process with respect to any Product on the effective date of termination shall be deemed to have been cancelled, unless this Agreement is terminated by
Forty Seven under Clause 14.2.1 or 14.2.2, in which case Forty Seven may elect, by provision of written notice to Lonza, for Lonza to complete manufacture of and deliver in accordance with the terms of this Agreement any such cGMP Batch in-process; 

  

	 	14.3.2	Subject to the other terms of this Agreement, within [*] days of receipt of an invoice therefor, Lonza shall be compensated for: 

  

	 	(a)	all Services rendered in accordance with this Agreement up to the date of termination, including in respect of any Product in process; and 

 

	 	(b)	all costs through the date of termination, including Raw Materials costs and Raw Materials Fees for Raw Materials used or purchased for use in connection with the Project Plan (as set forth in Section 2.6), in each
case, to the extent such costs were incurred in accordance with this Agreement. 

  

	 	14.3.3	Provided that Forty Seven has made all payments to Lonza in accordance with this Agreement, upon termination or expiration all unused Raw Materials and Forty Seven Materials and Product created pursuant to this
Agreement shall, at Forty Seven’s election, be delivered to Customer or disposed of by Lonza and in each case, at cost to Forty Seven. 

  

	 	14.4	ln the event of termination of this Agreement by Lonza pursuant to Clause 14.2.1 or 14.2.2, then in addition to Clause 14.3, [*] terminated by Lonza in accordance with Clause 14.2.1 or 14.2.2. 

 

	 	14.5	ln the event of termination of this Agreement by Forty Seven pursuant to Clause 14.2.4, then [*] in accordance with the terms of this Agreement and [*] obligations hereunder [*] until the earliest of [*] terminated by
Forty Seven in accordance with Clause 14.2.4, or (iii) the termination of this Agreement in accordance with the terms of Clause 14.2]. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 22. 

 

 
 CONFIDENTIAL 
  

	 	14.6	General. Expiration or termination of this Agreement for any reason shall not release any Party hereto from any obligation or liability which, as of the effective date of termination, has already accrued to the
other Party or which is attributable to a period prior to the effective date of termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.
Except as set forth in this Section 14.6 or 14.7, upon expiration or termination this Agreement shall be of no further force or effect. 

  

	 	14.7	Survival. Clauses 2.5, 2.9 (the last sentence thereof), 5, 7, 9, 10, 11.1.6, 11.2.5, 12, 13, 14, 15, and 16 shall survive the expiration or termination of this Agreement. 

 

	15.	Force Majeure 

  

	 	15.1	lf Lonza is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and gives written notice thereof to Forty Seven specifying the matters constituting Force Majeure
together with such evidence as Lonza reasonably can give and specifying the period for which it is estimated that such prevention or delay will continue, Lonza shall be excused from the performance or the punctual performance of such obligations as
the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. In such event, Forty Seven’s obligations under Clause B shall be suspended for so long as such Force Majeure shall continue. Provided
that, if such Force Majeure persists for a period of [*] months or more, either Party may terminate this Agreement by delivering written notice to the other Party. 

 

	 	15.2	“Force Majeure” shall be deemed to include any reason or cause beyond Lonza’s reasonable control affecting the performance by Lonza of its obligations under the Agreement, including, but not limited to,
any cause arising from or attributable to acts of God, strike, lockouts, labor troubles, restrictive governmental orders or decrees, riots, insurrection, war, terrorists acts, or the inability of Lonza to obtain any required raw material, energy
source, equipment, labor or transportation. 

  

	 	15.3	With regard to Lonza, any such event of Force Majeure affecting services or production at its Affiliates or suppliers shall be regarded as an event of Force Majeure. 

 

	16.	Miscellaneous 

  

	 	16.1	Severability. If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any
way be affected or impaired thereby. The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision which is as far as possible commercially equivalent considering the legal interests and the purpose.

  

	 	16.2	Amendments. Modifications and/or amendments of this Agreement must be in writing and signed by the Parties. 

  

	 	16.3	Performance by Affiliates. Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza’s obligations contained in this Agreement, but Lonza shall remain fully responsible in
respect of those obligations and shall be responsible for any action or omission of such Affiliate that would constitute a breach of this Agreement had such action or omission been conducted by Lonza itself. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 23. 

 

 
 CONFIDENTIAL 
  

	 	16.4	Assignment. Neither Party shall be entitled to assign, transfer, charge or in any way make over the benefit and/or the burden of this Agreement without the prior written consent of the other which consent shall
not be unreasonably withheld or delayed, save that Lonza shall be entitled without the prior written consent of the Licensee to assign, transfer, charge, sub-contract, deal with or in any other manner make
over the benefit and/or burden of this Agreement (i) to an Affiliate or (ii) to any joint venture company of which Lonza is the beneficial owner of at least fifty per cent (50%) of the issued share capital thereof or (iii) to any
company with which Lonza may merge or (iv) to any company to which Lonza may transfer substantially all of its business or assets and undertakings. Notwithstanding the foregoing, Forty Seven may, [*], assign this Agreement to [*].

  

	 	16.5	Notice. All notices must be written and sent to the address of the Party first set forth above. All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by facsimile followed
by hard copy delivered by the methods under (c) or (d), (c) by prepaid certified or registered mail, return receipt requested, or (d) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a
later date stated in the notice. 

  

	 	16.6	Governing Law/Jurisdiction. 

  

	 	16.6.1	This Agreement is governed in all respects by the laws of the State of New York without regard to its conflict of laws rules. Subject to Clause 16.6.2, the Parties agree to submit to the jurisdiction of the courts in
the State of New York. 

  

	 	16.6.2	Any dispute arising between the Parties under this Agreement will be referred to and finally settled by binding arbitration under the Rules of Arbitration of the International Chamber of Commerce by a single arbitrator
knowledgeable in biopharmaceutical research and development related matters and familiar with the biopharmaceutical industry, appointed in accordance with the said Rules. The place of arbitration shall be New York, New York and the arbitration shall
be conducted in the English language. The arbitrator’s award shall be final and binding. The Parties covenant and agree that they will participate in the arbitration in good faith and that they will share equally the costs of the arbitration,
except as otherwise provided herein. Judgment upon the award rendered in any such arbitration may be entered in any court of competent jurisdiction, or application may be made to such court for a judicial acceptance of the award and an enforcement,
as the law of such jurisdiction may require or allow, Notwithstanding the foregoing, nothing in this Clause 16.6 shall prevent either Party from applying to a court of competent jurisdiction for equitable or injunctive relief. 

 

	 	16.7	Rights of Third Parties. The parties to this Agreement do not intend that any term hereof should be enforceable by any person who is not a party to this Agreement, save that Affiliates of Lonza and Affiliates of
Forty Seven respectively may rely on the indemnities granted to them and limitations and exclusions of liability contained herein. The Parties may amend this Agreement without the consent of the Affiliates of either Party. 

 

	 	16.8	Announcements / Press Releases. Neither Party shall make any press release or announcement regarding the subject matter of this Agreement without the prior written consent of the other. The Parties shall use
reasonable efforts to issue a joint press release within thirty (30) days of the Effective Date regarding the entry into this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 24. 

 

 
 CONFIDENTIAL 
  

	 	16.9	Entire Agreement. This Agreement, including for clarity the Appendices hereto, prior MSA and GS Licence, contains the entire agreement between the Parties as to the subject matter hereof and supersedes all prior
and contemporaneous agreements solely with respect to the subject matter hereof. To the extent that any inconsistencies or conflicts exist among the terms of this Agreement and the Prior MSA, the order of governance shall be (1) this Agreement
and (2) the Prior MSA. 

  

	 	16.10	Stage 51. That certain amendment to the Prior MSA for a scope of Services known as “Stage 51” is hereby terminated by the Parties without incurring any payment obligation to Lonza, notwithstanding any
provision of the stage 51 amendment to the contrary, and the Services to be performed thereunder shall be performed under this Agreement. 

  

	 	16.11	Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. Each party
acknowledges that an original signature or a copy thereof transmitted by facsimile or by .pdf shall constitute an original signature for purposes of this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 25. 

 

 
 CONFIDENTIAL 
  

 IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be
executed by its duly authorized representative effective as of the date written above. 
  

					
	LONZA SALES AG
		
	By:	 	/s/ Bart A. M. van Aamhem
		 	Name	 	Bart A. M. van Aamhem
		 	Title	 	Senior Legal Counsel
		
	By:	 	/s/ Nadia Zieger
		 	Name	 	Nadia Zieger
		 	Title	 	Associate Director
		 		 	Key Account Management
	
	FORTY SEVEN, INC.
		
	By:	 	/s/ Jonathan MacQuitty
		 	Name	 	Jonathan MacQuitty
		 	Title	 	CEO

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 26. 

 

 
 CONFIDENTIAL 
  

 APPENDIX A 

Product and Project Plan 
 [*] (3
pages omitted) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 27. 

 

 
 CONFIDENTIAL 
  

 APPENDIX B 
  

	I)	Price 

 [*] 
  

	II)	OUTLINE TERMS FOR TEGHNOLOGY TRANSFER FROM LONZA TO FORTY SEVEN 

 [*] (4 pages omitted)

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 28. 

 

 
 CONFIDENTIAL 
  

 APPENDIX C 

Quality Agreement 

(TO BE ATTACHED) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 29. 

 

 
 CONFIDENTIAL 
  

 APPENDIX D 

Example Specifications 
 [*] (4
pages omitted) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 30. 

 

 
 CONFIDENTIAL 
  

 APPENDIX E 

[*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 31.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]